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CHAPTER 1: GENERAL INTRODUCTION: DISSERTATIONAL 
ORGANISATION 
This dissertation has 3 chapters. 
Chapter 1 includes a general introduction to the organization of the dissertation and the 
significance of the study included in the dissertation. 
The second chapter of this dissertation is a literature review that describes the work related 
to reported experimental studies. Aptamers are introduced in the first section of the second 
chapter. Then, a survey of the literature regarding therapeutically important aptamers and 
aptamers expressed in vivo are discussed. In this section, aptamers in all stages of clinical 
development and also aptamers utilized in various diseases such as cancer, diabetes are 
described. In the next section, on the topic of in-vivo expressed aptamers, other aptamers, such as 
those selected against the human immunodeficiency virus proteins are also discussed. How these 
various aptamers might aid in disease prevention or cure is also discussed in detail. In the next 
section of the literature review aminoglycoside antibiotics are described. The section starts with 
an introduction to aminoglycoside antibiotics. Then the aminoglycoside structure is described. 
This is followed by a discussion of how the aminoglycosides elicit their antibacterial effects. In 
addition, mechanisms that bacteria use to resist the effects of aminoglycoside antibiotics are also 
discussed.  
The current study is based on a mathematical model for the intracellular activity of 
aptamers, which proposes that aptamers or other small receptors for drugs can be used to 
increase the intracellular concentration of free (not aptamer-bound) drugs in target cells. This is 
discussed in the next section. In this study the model was tested using aptamers that recognize 
aminoglycosides. Therefore, aptamers selected to bind aminoglycoside antibiotics are introduced 
and the binding mechanisms of ligand with the aptamers are described. Natural and synthetic 
RNA that can bind with aminoglycosides are described in this section. The next section reviews 
bacterial cell structure, their growth phases and the inoculum effect. Throughout the entire study 
reported here, Escherichia coli bacterial cells were used for experimentation. Therefore, the 
review focuses on the growth characteristics of E. coli. First, the Escherichia coli morphology 
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and extracellular and the intracellular structural elements are described. Then, the growth of the 
E. coli is reviewed with reference to the various growth phases. In addition, the inoculum effect 
is described, which applies to the response of bacteria to certain aminoglycosides and other 
drugs. The mathematical model proposes that the mobility of the drug receptors is important. 
Therefore, the mobility of molecules in cells is reviewed. In this section first physical theories 
behind the mobility of molecules inside the cells are considered. Then techniques utilized to 
observe and measure mobility of molecules inside the cell are described. Two of the most mobile 
molecules in the cell are RNA and proteins. In this dissertation we concentrate on RNA 
aptamers. Therefore studies in of RNA mobility are discussed and related aspects of protein 
mobility inside the cells are also reviewed. Finally, the chapter of literature review ends with a 
discussion of research results related the study described in the dissertation. 
Chapter three describes studies in which aptamers were used to increase the intracellular 
drug concentrations in order to obtain more effective killing of cells. This study is focused on 
cancer cells, which require a very high drug concentration in order to obtain an effective killing 
of cancer cells. A major challenge in cancer treatment today is to provide a high enough drug 
concentration in order to obtain an effective killing of cancer cells. Cancer, medically known as 
malignant neoplasm is a disease that involves unregulated cell growth. Cancer cells have 
biological mechanisms that allow them to resist drug treatments, such as by increasing the 
expression of multi drug efflux pumps. Therefore, when undergoing chemotherapy, cancer 
patients should be given concentrations of drugs as high as possible in order to effectively 
destroy all the cancer cells. But, most drugs used in cancer chemotherapy are generally 
cytotoxic.  Thus, providing these drugs in high concentrations without targeted delivery can also 
be harmful to healthy cells. Since general toxicity of chemotherapy treatments is one of the 
major causes for deaths among cancer patients, increasing the effective intracellular drug 
concentration is extremely important. For this reason, the current study to test the ability of 
aptamers to increase the intracellular concentrations of drugs was initiated.  Before testing this 
idea in cancer cells, the simpler Escherichia coli bacterial cells were used as a model system. In 
this model system aminoglycoside aptamers that had been selected to bind with aminoglycosides 
with high specificity and affinity were used. These aminoglycoside RNA aptamers were cloned 
downstream of the T7 RNA polymerase promoter in an expression vector and used to test the 
questions: 1) can intracellular aptamers increase the concentration of drug in a cell?. And 2) can 
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intracellular aptamers increase the concentration of free drug (not bound to the aptamers) in the 
cell?. The first question was tested with Cy3-paromomycin that was used to determine the effect 
of expressing aptamers on the intracellular concentration of the drug. The second question was 
tested by determining the effect of aptamer expression on the growth of E. coli cells. If the 
expression of aptamers in the cells increases the concentration of free drug (which is not bound 
to the aptamer) that can bind to the ribosome and kill the cell, then the IC50 (half maximal 
inhibitory concentration) and the MIC (minimum inhibitory concentration) for the drug should 
decrease with aptamer expression. Both questions were answered in the affirmatory as 
demonstrated with the data shown in Chapter 3.  
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CHAPTER 2: LITERATURE REVIEW 
Aptamers 
Introduction to aptamers 
Aptamers are synthetic, single stranded nucleic acid molecules that fold into unique 3D 
structures allowing them to bind specifically and with a high affinity to their target molecules. 
There are also peptide aptamers although this discussion will focus on nucleic acid aptamers. 
The name aptamer comes from the latin aptus meaning to fit and Greek meros meaning regions 
(1). Therefore the word aptamer describes the oligonucleotide or peptide as having high 
specificity and affinity towards its target. In this sense, aptamers are the chemical equivalents of 
antibodies. In the therapeutic front, aptamers are always in competition with small molecules and 
antibodies. Aptamers can be used for therapeutic purposes in the same way as monoclonal 
antibodies. There are both advantages and limitations for the use of aptamers (1). One advantage 
of aptamers compared to antibodies is that aptamers can be produced chemically by readily 
scalable processes whereas antibody production requires traditional methods involving living 
organisms or cultured mammalian cells. Because of the biological mode production of 
antibodies, it is difficult to scale up production without affecting the product quality and 
characteristics. Antibody production is more prone to viral and bacterial contaminations that 
affect the product quality. On the other hand, the chemical production process of aptamers is not 
prone to bacterial and viral contamination. Aptamers are non- immunogenic whereas antibodies 
often elicit immunogenic reactions. The smaller sizes of aptamers allow them efficient entry into 
many biological compartments. But it also makes them susceptible to renal filtration which leads 
to a shorter blood half-life. On the other hand, although the larger size of antibodies prevents 
renal filtration giving them a longer half-life it also prevents their access to many biological 
compartments thus reducing their bioavailability. The short half-life of aptamers has been 
overcome by the addition of conjugation partners such as polyethylene glycol or cholesterol to 
increase the half-life. Also, the chemistries required for the addition of such conjugation partners 
to antibodies are nonspecific and therefore can produce mixtures of derivatives and reduced 
activity. Another advantage of aptamers is that they can be reversibly denatured and the 
phosphodiester bond is chemically very stable. Antibodies are irreversibly denatured and the 
shelf life is limited. But antibodies are not susceptible to nuclease degradation in the serum 
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whereas unmodified aptamers are highly inclined to nuclease degradation. Chemical 
modifications incorporated into the sugars or internucleotide phosphodiester linkages enhance 
nuclease resistance and such modifications of aptamers can be readily introduced during 
synthesis.      
Aptamers exhibit high affinities for their targets with Kd values often in the low nanomolar 
to picomolar range (2). Aptamers are very selective for their targets. In some instances, the 
specificity of aptamers enables their discrimination between closely related isoforms or different 
conformational states of the same target molecule (3). However, aptamers that recognize mouse 
and human protein targets with equal affinities can also be selected, making them suitable for 
both preclinical and clinical studies (4). Aptamers also have the ability to retain their specific 
binding ability and inhibitory behavior even after tagging with functional groups, delivery into 
animals and immobilizing on carrier materials (5).  
Aptamers are usually selected from random pool of oligonucleotide sequences libraries, 
but natural aptamers also exist in riboswitches (6). The process of selecting aptamers from 
oligonucleotide sequence libraries is termed as SELEX, standing for “Systematic Evolution of 
Ligands by Exponential enrichment”. In 1990 two labs independently developed this technique 
of selection (7,8). The Gold lab, used the term SELEX for their process of selecting RNA ligands 
against T4 DNA polymerase and the Szostak lab used the term In vitro selection for selecting 
RNA ligands against various organic dyes. The SELEX procedure is now highly recognized as a 
powerful tool for obtaining nucleic acid aptamers for almost any target molecule that can bind 
the nucleic acid with a high affinity and specificity. Since the discovery of aptamers and the 
SELEX procedure, many aptamers have been selected against a variety of targets molecules 
ranging from small molecules (9), peptides and amino acids (10,11), antibiotics and 
aminoglycosides (12), vitamins, carbohydrates and cell membrane proteins (13). Because 
SELEX is an in vitro process there is limitless opportunity for aptamers that recognize more and 
more target molecules and condition of selection. Therefore, new aptamers for different target 
molecules continue to be reported. 
Aptamers as therapeutics 
On the therapeutics front aptamers are new reagents although one aptamer is already in the 
market as an aptamer-based drug. Aptamers are also in several stages of development as 
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preclinical, clinical to FDA approved drugs (13). Aptamers have been developed as anticancer 
(14), antiangiogenesis (15), anticoagulation (16), for diabetes (17), antiviral (18) and 
antimicrobial (19).  
AS 1411 is a 26 nt G-rich DNA aptamer and one of the first reported anticancer aptamers. 
AS1411 targets nucleolin, a nuclear matrix protein that can also be found on the surfaces of the 
cancer cells. AS1411 consists only of guanines and thymines. AS1411 was not discovered by the 
general SELEX procedure but as a part of a screen for antisense oligonucleotides for 
antiproliferative activity (20). The AS1411 aptamer has been very effective in many preclinical 
cancer and animal models such as human breast cancer, lung cancer, pancreatic cancer and acute 
myelogenous leukemia (21). The proposed mechanism of anticancer activity by AS1411 is that 
internalization of the aptamer by cell surface nucleolin and subcellular inhibition of the 
transcription factor, nuclear factor-ĸB (22) also destabilization of the mRNA encoding the anti-
apoptotic, B-cell lymphoma protein 2 (BCL2) (23). AS1411 is being developed by Antisoma 
Research and currently on phase II clinical trials for acute myeloid leukemia.  
Another aptamer developed for cancer treatment is the NOX-A-12 aptamer. NOX-A-12 
aptamer is in clinical development by NOXXON Pharma AG. It is a spiegelmer selected by a 
variation of the SELEX procedure. Spiegelmers are selected from a wild type (D-RNA) library 
using mirror image target (D-amino acids), but they are synthesized as L-RNA in order to bind 
with the wild type target (L-amino acids) (13). The reason for selecting this type of aptamer is 
that the L-RNA aptamer that binds to the natural target is resistant to nuclease degradation. 
Therefore they are stable in human plasma for over 60 hours at 37⁰C. NOX-12 was selected to 
bind to chemokine ligand 12, which is a chemokine involved in angiogenesis, cell homing, tumor 
metastasis and tissue regeneration. The NOX-A-12 aptamer is 45nt L-RNA aptamer conjugated 
at the 3’ end with polyethylene glycol (PEG).  It is currently under phase IIa clinical trial for the 
treatment of chronic lymphocytic leukemia (CML), multiple myeloma. NOXXON has also 
developed clinical trials for NOX-A-12 in glioblastoma.  
Aptamers are also being developed as anti-coagulation agents. Anticoagulants are a major 
class of pharmaceutical agents used to prevent blood clotting in clinical procedures and in 
cardiovascular diseases. Heparin, highly sulfated glycosaminoglycan is currently being used as 
an anticoagulant, but it has some negative effects such as spontaneous hemorrhage and reduction 
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of blood platelet. Also heparin produces allergic reactions in some patients. Due to these reasons 
much attention has been given to discovering novel anticoagulants. One such novel discovery is 
NU172 DNA aptamer, selected to bind and inhibit thrombin. Thrombin is a serine protease and a 
key activator of several proteins in the coagulation cascade. NU172 was selected by the SELEX 
procedure from DNA library and later truncated to 26nt long without additional modifications. 
NU172 is administered intravenously during cardiovascular surgical procedures to prevent blood 
clotting. NU172 aptamer is currently undergoing phase II clinical trials to be used for 
anticoagulation in heart disease treatment by ARCA Biopharma. 
A breakthrough in aptamer technology occurred in December 2004, when the FDA 
approved the first aptamer based drug. Pegaptanib, brand name Macugen, is an anti-vascular 
endothelial growth factor (VEGF) RNA aptamer. It is an anti-angiogenic therapeutic agent for 
neovascular (wet) age-related macular degeneration (AMD), a disease in the eye that causes loss 
of central vision leaving only peripheral or side vision intact (24).  The target of Pegatanib is 
VEGF165, the most abundant VEGF isoform that regulates vascular permeability. Pegatanib binds 
to the heparin binding domain of the VEGF165 and inhibits VEGF binding to its receptor, thereby 
inhibiting the growth of blood vessels. During selection Pegatanib was only modified at 
pyrimidine residues by using 2ʼ-fluoro substituted precursors. After selection of the aptamer the 
purines were stabilized by 2ʼ-O-methyl residues resulting in high nuclease resistance. To 
increase the half-life and stability of the aptamer in the biological conditions the 5’ terminus was 
also modified by 40 kDa polyethylene glycol (PEG) along with an inverted 3’-3’-
deoxythymidine cap (25). 
Phase I clinical trials for aptamers in diabetes have also been performed using the 
spiegelmer, NOX-E36. This aptamer binds to chemokine ligand 2, a cytokine involved in 
recruiting monocytes, T cells and dendritic cells to the site of injury. NOX-E36 greatly decreases 
glomerulosclerosis in type 2 diabetes in mouse models (17). NOX-E36 is 40nt aptamer with 3’-
terminal PEG9 (26). 
Aptamers expressed inside the cells 
Aptamers selected by in vitro SELEX procedure has been used for inside the cells to serve 
many purposes (27). There is a new appreciation for the role that can be played by aptamers both 
in vitro and in vivo. Aptamers selected by SELEX are being used inside the cell for several 
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purposes including (1) to antagonize the normal cellular proteins as method of elucidating their 
biological roles (2) as a decoy of naturally occurring RNA binding proteins to dissect their 
function (3) to regulate the expression of exogenous genes and (4) to counteract disease related 
targets for potential biomedical applications. 
Binding of an RNA aptamer to its target often inhibits the target’s activity in vitro (28). 
Most aptamers have their origins in test tubes; therefore there is no inferential reason as to why 
they would work in the same way in vivo. But, in many instances in vitro-selected aptamers 
retain their binding ability inside the cells. One example is an RNA aptamer designated FC that 
bind RNA polymerase II holoenzyme from the yeast Saccharomyces cerevisiae with dissociation 
constant (Kd) of 20nM (29).  Aptamer FC inhibits in vitro transcriptional initiation but not 
elongation, by RNA Pol II. Also this aptamer does not inhibit in vitro transcription by RNA Pol I 
or RNA Pol III of S. cerevisiae by Pol II from Saccharomyces pombei. To observe the RNA Pol 
II inhibition in S. cerevisiae by the FC aptamer, DNA encoding the aptamer was cloned 
downstream of a Pol III dependent RNase P RNA promoter (RPR1) and expressed in yeast cells. 
The large subunit of RNA Pol II was then placed under the LEU 2 promoter. When these cells 
were placed in leucine-rich medium, transcription from the LEU2 promoter was suppressed 
resulting in low Pol II levels, but overall cell growth was not affected. Cells expressing the FC 
aptamer grew normally in low leucine medium while their growth was drastically inhibited in 
high leucine medium.  Also aptamer expression in otherwise wild type cells did not affect the 
cell growth. In this example it shows that inhibition of yeast RNA Pol II had a distinct effect 
only when RNA Pol II concentration was limiting.  
One instance where aptamers were used to investigate the function of RNA binding 
proteins in natural transcripts was a study by Shi et al. of the anti SR protein B52 aptamer (30). 
SR proteins are required in Drosophila for constitutive and alternate pre-mRNA splicing. Over 
expression or deletion of B52 protein results in severe growth defects in Drosophila. Shi et al. 
(30) selected an aptamer that binds protein B52 with a Kd of 20-50 nM. They expressed this 
aptamer in Drosophila as a multimeric array of 5 aptamers and observed the growth effects (31). 
For transgenic flies that carried the aptamer array, but which were otherwise wild type, survival 
to adulthood was reduced by 50 percent. For flies engineered to over express B52, the 
developmental defects were largely rescued.   
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Another example of an aptamer selected in vitro that retains its binding activity in vivo is 
an RNA aptamer selected against the nucleocapsid protein of the human immunodeficiency 
virus-1 (32). When expressed in cells, this aptamer prevented packaging of the viral genomic 
RNA (33). The same aptamer inhibited the nucleocapsid binding to the stable transactivation 
response hairpin and psi RNA stem loops of HIV-1 RNA (33).   
Aptamers selected to bind with small molecules have also been used as functional units in 
vivo. Grate and Wilson (34) showed that, when inserted in the 5’ UTR of the cyclin transcript in 
the Sacchromyces cerevisiae, an aptamer sequence selected to bind with malachite green reduced 
the rate of cell cycle transit depending on the absence or the presence of the target ligand. The 
malachite green binding motif of the aptamer which is an internal bulge flanked by short RNA 
helices, was inserted immediately upstream of the CLB2 start codon. When tetramethylrosamine 
(a fluorescent malachite green analogue) was added to the aptamer containing yeast strain, 
progress through the cell cycle was significantly slowed and elongated bud morphology was 
observed. Quantification of the CBL2 expression at the RNA and protein levels by RT-PCR and 
western blot analysis, respectively, showed that aptamer ligand interaction regulated the 
transcript translatability rather than the transcript stability. They also performed one dimensional 
NMR spectroscopy to demonstrate that ligand binding to the aptamer results in a significant 
change in the structure of the aptamer with many nucleotides folding to adopt a well-defined 
conformation. With these results they concluded that translational initiation is blocked by a 
ligand induced conformational change in the 5’-UTR. Wersturk and Green (28) showed that 
when RNA aptamers selected to bind with the small antibiotic molecules tobramycin and 
kanamycin were present in the 5’ UTR of an mRNA construct they could repress the translation 
of that gene in an in vitro translation assay. They inserted three copies of the tobramycin binding 
aptamer in the 5’ UTR of an mRNA construct and cap dependent translation in wheat germ 
extract was near normal when no antibiotic was present, but was reduced to ten percent in the 
presence of 60 μM tobramycin. No growth inhibition was observed when the 5’ UTR had no 
aptamer or when 60 μM kanamycin was used in place of tobramycin with the tobramycin multi 
aptamer (28). They translated the mRNA construct containing the aptamer in vitro in the 
presence of [
35
S] methionine using a wheat germ extract. The protein products were analyzed by 
SDS-polyacrylamide gel electrophoresis (PAGE) and quantified by densitometry. Wersturk and 
Green also replaced the aminoglycoside aptamers with one copy of the Hoechst aptamer in the 5’ 
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UTR of a mammalian β-galactosidase RNA in an expression plasmid.  Chinese hamster ovary 
cells (CHO) were transfected with this plasmid. As a control, another vector without Hoechst 
aptamer was used. The luciferase reporter gene was used to provide an internal control. Addition 
of the Hoechst dye after 24 h transfection reduced β-galactosidase activity to five to ten percent 
of that observed without the dye. In the absence of the dye binding aptamer in the 5’UTR neither 
β-galactosidase nor luciferase activity (from co-transfected control DNA) was affected by the 
addition of the dye proving that dye itself has no global effect on translation. This technique can 
be utilized in gene therapy applications. That is activity of an exogenous transfected gene could 
be regulated through small molecules for which the dosage can be controlled. Aptamers 
interactions with small molecule targets are also retained in bacterial cells. Wersturk and Green 
(28) expressed tobramycin and kanamycin aptamers in E. coli that were then incubated with the 
aminoglycosides, tobramycin or kanamycin, respectively. Expressing one copy of the 
aminoglycoside aptamer allowed bacterial cells to grow at otherwise lethal concentrations of 
aminoglycosides. Expressing three copies of the aptamer allowed more vigorous growth than 
expressing one copy at otherwise lethal aminoglycoside concentrations.  They concluded that the 
aptamers rescued the cells from killing by the aminoglycosides because they competed with the 
ribosome for binding these inhibitors. 
One very important aspect of in vivo expressed aptamers is their potential biomedical 
applications. In the previous section on aptamers in therapeutics, aptamers directed against extra 
cellular targets were discussed. This potential has promoted the development of pharmaceutical 
companies like Archemix, NexxonPharma AG, Gilead science, Ribozyme Pharmaceutical and 
others. However, the ability of in vitro selected aptamers to function in vivo expression adds to 
the possibilities for medical and other applications. As the following examples suggest, there is 
substantial promise that aptamers can eventually be used to treat diseases like cancer, 
inflammatory diseases, sleeping sickness and Acquired Immune Deficiency Syndrome (AIDS). 
Curing diseases caused by viruses has been a challenge for decades, especially after 
the emergence of Human Immunodeficiency Virus (HIV). Although there are some therapeutics 
for HIV, they are often unsuccessful because of drug resistance conferred by mutations in the 
viral genome. One of the essential proteins of HIV is its Reverse Transcriptase (RT), which 
converts the RNA genome into double stranded DNA that can be inserted into the host genome. 
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It is important to target an essential gene product such as RT for efficient prevention of the 
disease. Therapeutics against RT is one of the most novel forms of antiviral remedies for HIV 
today. Aptamers directed against RT inhibits its polymerization activity in vitro (35).  Aptamers 
selected to bind RT fold as pseudo-knots inside the cells and bind with RT with Kds in the low 
nanomolar range. Recently a new aptamer was discovered that binds RT with a Kd in the low 
picomolar range (36). The ability of this anti RT aptamer to disrupt the RT activity in E. coli has 
already been assayed (37).  
One drawback of antiviral therapeutics is that the therapeutics cannot keep up with the 
high mutation rate of viruses. In that context aptamers have an attractive solution to this problem, 
because refinements of aptamers can generate aptamers that can inhibit the mutant viral forms.  
Homann and Goringer (38) reported an aptamer that binds with the outer surface of 
the live Trypanosoma brucei, the parasite responsible for sleeping sickness. This aptamer binds a 
single 42 kDa protein located at the base of the flagella apparatus on the trypanosome. This 
flagella pocket is responsible for transporting cargo in and out of the parasite. The authors have 
shown that, after endocytosis of the aptamer, there is a secondary structural core that remains 
intact in the parasite’s lysosome. Also they show, using biotinylated or fluorescently-tagged 
aptamers, that these aptamers can be used to shuttle materials into the trypanosome. Although 
this aptamer does not destroy the parasite it can be utilized to deliver materials to kill the 
parasite. 
The examples given above bring out some important aspects of aptamers for their use 
as therapeutics and as in vivo expressed aptamers. One very striking aspect is that in vitro 
selected aptamers retain their binding characteristics even when they are expressed inside the 
cells.  These results emphasize two important factors of in vivo expressed aptamers. First, 
aptamers retain their binding and inhibitory ability inside the cells. Second, it is very important 
to balance the level of aptamer accumulation, target expression level and cell sensitivity to target 
expression level. Being very amenable to modification and optimization, aptamers provide an 
exciting route for future research and application.  
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Aminoglycoside antibiotics 
Structure of aminoglycosides 
Aminoglycoside antibiotics are one of the earliest known classes of antibiotics with a 
broad spectrum activity against gram-negative and gram-positive bacteria, as well as 
mycobacterium. They are poly cationic molecules with high flexibility. Aminoglycosides have 
amino sugars, glycosidically linked to aminocyclitols. The aminoglycosides have been classified 
into two major groups depending on whether the aminocyclitol is of the streptidine or 2-
deoxystreptamine class (39). The 2-deoxystreptamine class of aminoglycoside is further 
categorized depending on the linkage of amino sugars to the non-sugar 2-deoxystreptamine ring. 
Tobramycin (Figure 1), which belongs to the kanamycin subgroup of antibiotics, has pyranose 
sugars attached at the 4 and 6 positions of the 2-deoxystreptamine ring. Neomycin-B (Figure 1) 
along with paromomycin and lividomycin belong to the neomycin subgroup of aminoglycoside 
antibiotic that has a pyranose sugar attached to the 4 position and a furanose-pyranose pair of 
sugars attached to the 5 position of the 2-deoxystreptamine ring.  Aminoglycosides, being poly 
cationic molecules, bind various RNA molecules and inhibit their biological activity. 
Role of aminoglycosides in bacterial growth inhibition 
Aminoglycosides achieve their antibiotic activity by interfering with protein synthesis in 
prokaryotic cells. The Neomycin class of aminoglycoside antibiotics bind to the 16S ribosomal 
RNA and inhibit protein synthesis (40). Uptake of aminoglycosides occurs in three phases; first 
they bind with negatively charged lipopolysaccharides, phospholipids, and negatively charged 
segments of protein on the cell wall and the plasma membrane of gram-negative prokaryotes 
because of their polycationic nature at physiological pH (41,42). Bound aminoglycosides 
displace the Mg
2+
 and Ca
2+
 ions that bridge the lipopolysaccharides in the outer membrane and 
disrupt membrane integrity. The second phase of aminoglycoside uptake is an energy and 
concentration dependent process (43). This phase is called as the Energy Dependent phase I 
(EDPI) (41). This process requires threshold potential (Δp) generated by a proton motive force.  
The third phase of aminoglycoside uptake is also energy dependent, called Energy Dependent 
phase II (EDPII), and involves an accelerated linear rate of aminoglycoside transport across the 
cytoplasmic membrane by a process that uses energy from electron transport and hydrolysis of 
adenosine triphosphate (ATP). This is supported by the observation that aminoglycoside uptake 
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during EDPII can be inhibited by cyanide, sulfhydryl reagents and uncouplers of oxidative 
phosphorylation (42). The binding of aminoglycosides to the ribosome results in interference 
with translation, incorporation of nonfunctional mis-read proteins into the membrane, and 
disruption of membrane integrity. This in turn increases the membrane leakiness to 
aminoglycosides.  
Translation of mRNA into protein is a complex process that occurs on the ribosome and 
requires decoding of the genetic code by selection of the correct amino-acyl-tRNAs. The 
integrity of aminoacyl-tRNA selection involves selection of the correct amino acyl-tRNA and 
proofreading by the ribosome. Aminoglycosides disrupt the decoding process by promoting 
misreading of the genetic code through their interaction with specific sites in the 16S rRNA (44). 
In the decoding process the anticodon triplet on the tRNA pairs with its cognate codon on the 
mRNA and protects bases on the 16S rRNA from chemical modification in the same region as 
the aminoglycosides bind.  The decoding site consists of nucleotides 1400-1410 and 1490-1500 
that form a stem-loop-stem structure, which is also known as the A site of the Escherichia coli 
ribosome (45). Decoding is accomplished by the interaction of the A site with the backbone of 
the codon-anticodon helix, thereby protecting the position N1 of A1492 and A1493 from 
chemical modification (44). The result of aminoglycoside binding by the A-site is dislocation of 
two conserved adenine residues, A1492 and A1493 to minor groove of the A site. This 
conformational change turns the A-site into high affinity site to tRNA-mRNA interaction thus 
reducing the rejection rate for near cognate tRNAs. In this way aminoglycosides inhibit the 
translocation of the tRNA-mRNA from the A-site to the peptidyl-tRNA site (P-site). Thus 
aminoglycosides cause a misreading of the genetic code and produce misread proteins.  For some 
time, obtaining a high resolution structure of aminoglycoside bound to the ribosome “A site” was 
not possible due to the large size of the ribosome. Therefore an alternative approach was adopted 
of determining the solution structure of a subdomain of the E. coli 16S rRNA bound with 
aminoglycoside using Nuclear Magnetic Resonance (NMR). Figure 2 shows the NMR solution 
structures of 27mer A-site RNA alone  and Figure 3  shows the NMR solution structure of 27 
mer A site RNA bound with paromomycin (46) , Figure 4 shows the secondary structure of the 
A-site RNA, with the bases that are protected by the neomycin class of aminoglycosides 
indicated by the triangles. The antibiotic binding site is the asymmetric internal loop (shown in 
blue in figure 2) that is defined by a Watson-Crick base pair C1407-G1494 at its outer limits and 
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by the non-canonical base pairs U1406-U1495 and A1408-A1493. The upper and lower stems 
are connected by a continuous interrupted helix with a widened major groove that allows 
docking of the antibiotics. The antibiotic binding pocket is composed of the base pairs A1408-
A1493 and the single bulged adenine A1492. Rings I and II of the aminoglycosides have specific 
contacts with the RNA. As an example, in the complexes of paromomycin (Figure 3), ring I is 
stacked upon G1491 and ring II is spans the base pairs U1406-U1495 and C1407-G1494. Ring 
III of paromomycin is positioned differently. Binding of the aminoglycosides to RNA induces a 
conformational change in the RNA, displacing the two universally conserved residues A1492 
and A1493 toward the minor groove, thus switching the A-site into a higher affinity site for 
mRNA-tRNA recognition and reducing the rejection rate of near-cognate tRNAs (46). This 
increased affinity of the A-site for tRNA is believed to result in misreading of the genetic code. 
This NMR structure of the A-site provided the first structural rationale for the functioning of 
decoding site. One very important outcome of work of Puglisi et al. (47) was the finding that the 
decoding site is an irregular helix that bind antibiotics by its major groove and makes contact 
with the anticodon on the tRNA through its minor groove. The first evidence that formation of 
the codon-anticodon complex includes contact through the 2’ hydroxyl group of the codon was 
finding that the 2’ hydroxyl group in the mRNA is required for tRNA binding (48). The 
additional evidence of rescue of a mutation in the A-site by 2’ modifications of the codon 
resulted in the proposal that minor groove-minor groove interactions between the decoding site 
and the mRNA stabilize the codon-anticodon duplex (49). In summary, the biochemical and 
biophysical evidence locates the aminoglycoside binding site on the ribosome as the adenine-rich 
internal loop at the 3’-end of the helix 44 in the 16S rRNA of the 30S ribosomal subunit, the 
latter consists of 16S rRNA and 21 proteins. The helix 44 binds aminoglycosides through its 
major groove and connects with the codon-anticodon complex via its minor groove. 
Paromomycin, neomycin and other aminoglycosides can also prevent assembly of the 30S 
subunit resulting in the accumulation of the 21S intermediate that is required for 30S subunit 
formation. Aminoglycosides bind preferably with prokaryotic ribosomes over eukaryotic 
ribosomes resulting in selective protein synthesis inhibition of prokaryotes. Therefore these 
aminoglycosides have been used as antibacterial drugs for a long time. 
As with other antibiotics, the challenge of multi drug resistance includes aminoglycosides. The 
misuse of aminoglycosides has resulted in bacteria that are resistant to their effects. There are 
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three major mechanisms by which bacteria resist aminoglycosides; which are: 1) inactivation of 
aminoglycoside drugs by aminoglycoside modifying enzymes, 2) ribosome alteration, and 3) 
decreased permeability to aminoglycosides. Of these, modifying the ribosome is not very 
common because the ribosome is the center of the protein synthetic machinery and is well 
conserved over evolution. But there are reports that modified ribosomes can lead to bacterial 
resistance. For example, ribosome alterations brought problems in treating tuberculosis 
(50).Streptomycin is used for Mycobacterium tuberculosis. Streptomycin acts by binding to 
the16S rRNA of Mycobacterium tuberculosis and interferes with protein synthesis. All the 
streptomycin-resistant Mycobacterium tuberculosis isolates have point mutations that result in 
changes in the streptomycin binding site (50). The second way of developing aminoglycoside 
resistance is by changing permeability for the aminoglycosides. One major mechanism by which 
microorganisms achieve is this by up regulating the expression membrane efflux pumps (51). 
Efflux pumps are transport proteins involved in extrusion of toxic substance (including all of 
antibiotics) from the interior to the exterior of the cell. These are present in gram negative, gram 
positive and eukaryotic cells. In prokaryotic cells there are five major families of efflux 
transporters. Those are MF (major facilitator), MATE (Multidrug and Toxic Extrusion), RND 
(Resistant Nodulation Division), SMR (Small Multidrug Resistance) and ABC (ATP Binding 
Cassette) (52). Aminoglycosides are exported from E. coli by the AcrD pump, which belongs to 
the RND family (53). Drug efflux promoted by AcrD is mainly determined by a pair of large 
loops containing more than 300 amino acid residues each, which reside in the  periplasmic space 
(52,53). The third method by which aminoglycoside resistance is achieved is by the action of 
aminoglycoside modifying enzymes. There are three major classes of aminoglycoside modifying 
enzymes. This classification was made based on the specific biochemical reaction these enzymes 
catalyze. They are 1) acetyltransferase (AAC) that transfer the acetyl group of acetyl CoA to an 
amino group of the aminoglycoside; 2) adenyltransferases (ANT) that transfer the adenosine unit 
of ATP to a hydroxyl group of an aminoglycoside or 3) phosphotransferases (APH) that transfer 
a phosphate group of ATP to a hydroxyl group of an aminoglycoside (54). Enzymes of these 
three classes have been classified into subclasses depending on the position they modified 
functional group. Acetyltransferases (AAC) modifies amino groups at 1, 2’, 3 and 6’. Therefore, 
further classification of these enzymes would be AAC (3), AAC (6’) and so on. The 
phosphotransferases (APH) are further classified as APH (3’), APH (3”), APH (4), APH (6), 
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APH (7”) and APH (9) depending on the modified hydroxyl group on the aminoglycosides. The 
adenyltransferases (ANT) are classified as ANT (2”), ANT (3”), ANT (4’), ANT (6) and ANT 
(9) depending on the modified hydroxyl group on the aminoglycoside. Also, groups of enzymes 
are further classified into subgroups depending on the individual substrate profile. For an 
example in the AAC (3) family there are at least 9 members named ACC (3)-I, AAC (3)-II and 
continuing up to AAC (3)-X. Aminoglycoside resistance is more complicated by the fact that 
there is more than one gene encoding for one AAC enzyme type. As an example in the enzyme 
family of AAC (6’)-I there are more than 18 specific genes (55). Therefore the battle with 
aminoglycoside drug resistance in bacteria is complicated.  
Aminoglycoside aptamers 
 Small RNA-aminoglycosides have been well-studied over the past few decades (28). 
Using thermodynamic and electrostatic experimental evidence, Jin et al. (56) demonstrated that 
aminoglycosides are major groove binders in duplex RNA.  They used a combination of 
spectroscopic, calorimetric, viscometric and computational modeling techniques to characterize 
binding of the aminoglycoside tobramycin to the polymeric RNA duplex poly(rl).poly(rC),  
which adopts a distinct A-type conformation that is very common among the natural and 
synthetic double helical RNA sequences (56). Similarly, like for the ribosomal RNA, 
aminoglycosides can bind to the hair pin loop structures and internal bulges. An example is 
aminoglycosides interacting with the Rev Responsive Element (RRE) of the Human 
Immunodeficiency Virus (HIV) (57). HIV replication depends on the interaction of the viral 
protein, Rev with the viral RNA, Rev Responsive Element (RRE). RRE has a high affinity core 
region for the protein, Rev, which is important for this protein-RNA interaction. This core region 
of the RRE has a noncanonical base pair (G48:G71) that is very important for rev recognition. 
Aminoglycosides, specially neomycin-B, specifically bind to the RRE and inhibit interaction of 
the RRE with Rev both in vitro and in vivo (57). Other than the RRE, aminoglycosides can 
interact with the Trans-Activating Response Element (TAR element) in HIV-1 RNA (58). The 
TAR element and Tat protein interactions with the HIV-1 RNA genome are very important for 
transcriptional initiation of HIV and this interaction is inhibited by the aminoglycoside 
neomycin-B.  Aminoglycosides also bind with other RNA regions like self-splicing group 1 
introns (59), the hammerhead ribozyme (60), and site 1 of thymidylate synthase mRNA (61).  
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Synthetic RNAs have been selected that bind aminoglycosides with high affinity and high 
specificity. Those are the aminoglycoside aptamers. Aptamers have been selected against the 
aminoglycosides neomycin-B, tobramycin, kanamycin-A, and paramomycin (62). The predicted 
secondary structures of some of the in vitro selected aptamers and natural aptamers are illustrated 
in the Figure 5. Jiang et al. (62) characterized the binding interactions between the 
aminoglycoside aptamer and the neomycin-B aminoglycoside. The neomycin-B aptamer is a 23 
nucleotide long RNA molecule with a secondary structure predicted as shown in Figure 5. As 
illustrated in Figure 6  in the complex between neomycin-B and the neomycin-B 23mer aptamer, 
the neamine component (ring I and ring II) of neomycin-B is sandwiched between the major 
groove floor of the zippered up “G●U” mis-matched nucleotide section and the looped out 
purine base that flaps over the bound aminoglycoside. Also, distinct hydrogen bonding 
interactions occur between the neomycin-B and mismatch base edges and the phosphate 
backbone. These interactions fasten the 2-deoxystreptamine ring I and pyranose ring II in the 
RNA aptamer binding pocket. Both the tobramycin and neomycin-B aptamers bind their 
respective ligands, neomycin-B and tobramycin, in a similar fashion in which the 2-
deoxystreptamine ring I and attached pyranose rings are captured in the major groove binding 
pocket consisting of the mismatch base pairs and the bound aminoglycoside is covered by looped 
out base and held in place by intermolecular hydrogen bond interactions between the charged 
amine groups of the aminoglycosides and charged residues of the RNA.   
Aminoglycoside aptamers are RNA molecules created by in vitro selection and evolution 
techniques to bind with the aminoglycoside antibiotics with high affinity and specificity. Even 
though aptamers are not of biological origin, determination of the structures of aptamer-ligand 
complexes aids in understanding the roles of diverse folding topologies of RNA in molecular 
recognition. Aminoglycoside-aptamer interactions exemplify the structural principles that govern 
the specific and high affinity interactions that exist in complexes of aminoglycosides with natural 
RNA. Also the in vitro selected aminoglycoside aptamers seem to have very useful applications 
in treating diseases such as HIV (57). Therefore aptamers selected against aminoglycosides pave 
the way to exciting new arenas in medicinal chemistry. 
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Figure 1. Chemical structures of aminoglycosides and the pKa values of some amine    
groups. Reprinted from (40) with permission. 
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Figure 2. Single representative structure of A-site RNA oligonucleotide. The core of the 
antibiotic binding site within the RNA (nucleotides U1406 to A1410, and U1490 to U1495) is 
shown in light blue and RNA residues outside the core are in green. All heavy atoms are 
displayed. From (40) with permission. 
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Figure 3. Single representative structure of A-site RNA in complex with paromomycin. The 
core of antibiotic binding site within the RNA is shown in (nucleotide U1406 to A1410 and 
U1490 to U1495) is shown purple and the residues outside the core is shown in green. 
Paromomycin is shown in tan. All heavy atoms are displayed. From (40) with permission. 
 
 
 
Figure 3 
21 
 
 
 
Figure 4. Secondary structure of the A-site RNA oligonucleotide showing the DMS 
footprints observed in the presence of aminoglycosides and marked with Δ. From (40) with 
permission. 
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Figure 5. Predicted secondary structures of the some aminoglycoside RNAs. Diagram of 
secondary structures of RNA aptamers that have been proven to interact with aminoglycosides. 
These RNA aptamers are in vitro selected RNAs to bind with specific aminoglycoside 
antibiotics. The secondary structures of RNA aptamers shown here were predicted with the RNA 
Structure 4.6 software and then reconstructed in Adobe Illustrator (63). 
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Figure 6. Neomycin-B-RNA complex. The RNA folds are shown in stick and ribbon 
representation, with the flapped base shown magenta. The bound aminoglycoside antibiotics are 
shown as space filling models. Ring I and II of the Neomycin-B antibiotic are shown in yellow 
and red, respectively. Ring III and IV are in white. The white arrow indicates the postulated 
linkage site of the neomycin-b through its primary amine moiety to the agarose column. From 
(62) with permission. 
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Bacterial growth 
Bacteria constitute a large group of prokaryotic microorganisms that are usually a few 
micrometers in length and of a variety of shapes ranging from rods, spheres and spirals (64). 
Bacteria were among the first life forms on earth (64). Even today, bacteria are present in most 
habitats on earth. In our study we mainly studied Escherichia coli, commonly abbreviated          
E. coli, which is a gram negative, facultative anaerobic rod shaped bacteria. In nature it is mostly 
found in the lower intestine of warm blooded animals (endotherms). Most E. coli strains are 
harmless, but some strains cause food poisoning in humans (65). The harmless strains are part of 
the bacterial flora in the gut and give the host the benefit of producing vitamin K2 (66).  This 
flora can also prevent the effects of pathogenic bacteria by inhibiting the establishment of 
pathogenic bacteria with in the intestine (67,68). Escherichia coli can be grown in laboratory 
settings very inexpensively. E. coli has been used as a model organism in many research studies 
for over 60 years. It is an important organism in recombinant DNA technology. In 1885 German 
pediatrician Theodor Escherich found this organism in feces of an individual and named it as 
Bacterium coli commune since it was discovered from in the colon. Later it was named as 
Escherichia coli.  
Biology and Biochemistry of Escherichia coli. 
E. coli is a gram negative, facultative anaerobic and non-sporulating.  The cells are 
typically rod shaped and are about 2.0 μm long and 0.5 μm in diameter with a cell volume of 
about 0.6-0.7 μm3.   E. coli can survive on a range of substrates (69). Under anaerobic conditions 
E. coli uses mixed acid fermentation and produces lactate, succinate, ethanol, acetate and carbon 
dioxide. Optimal growth of E. coli occurs at 37⁰C and some engineered strains can multiply even 
at temperatures of 49⁰C (70). They can grow under aerobic and anaerobic conditions utilizing a 
wide range of redox pairs, which includes oxidation of pyruvic acid, formic acid, hydrogen and 
amino acid. The reduction substrates are oxygen, nitrate, fumarate, dimethyl sulfoxide (71).      
E. coli has the capacity to transfer DNA by bacterial conjugation, transduction or transformation 
to spread genetic material through an existing population. This is called horizontal spread of 
genetic material.  
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Cellular structure of Escherichia coli 
Extracellular structure 
Escherichia coli have adhesive fimbriae and a cell wall (72). The cell wall is comprised of 
an outer membrane that contains lipopolysaccharides, a periplasmic space with a peptidoglycan 
layer and an inner cytoplasmic membrane.  The outer cell wall has an overall negative charge 
because it contains lipopolysaccharides and phospholipids. Escherichia coli cells have fimbriae 
attached to the cell wall. Fimbriae are protein tubes that extended out from the outer membrane. 
They are usually short in length and present in high numbers all over the bacterium. Function of 
the fimbriae is to facilitate the attachment of bacteria to surfaces to other cells such as in animal 
cells in pathogenesis.  
The bacteria cell is surrounded by a lipid membrane also known as the cell membrane or 
plasma membrane (45). This membrane acts as barrier to hold materials inside the cell and as 
well encircles the contents of the cell. All the nutrients, proteins, essential components are held 
in the cytoplasm. E. coli do not have membrane bound organelles such as a  true nucleus, 
mitochondria, chloroplasts and lysosomes that are present in the eukaryotic cells, but they have 
some large intracellular structures. The bacterial cytoplasmic membrane is a phospholipid bilayer 
with the features of a general cell membrane such as acting as a permeability barrier for most 
molecules and serving as location for the transporters that determine which molecules get into 
the cell (64). The cytoplasmic membrane contains electron transport proteins that can generate 
the proton motive force in bacteria. The E. coli membrane also contains the proportions of fatty 
acids that provide it the fluidity.  In the phospholipid bilayer the lipid portion is not very 
permeable to molecules, therefore the outer membrane contain channels called porins which 
allows passive transport of many ions, sugars and amino acids. The periplasmic membrane 
contains the peptidoglycans and many proteins required for signal transduction. The periplasm 
exists in a gel like state as high concentrations of proteins and lipids are dissolved in it. Important 
biochemical reactions, such as energy generation, utilize concentration gradients across the 
membrane. Because E. coli lack internal organelles, processes like the electron chain reaction 
take place between the cytoplasm and the outer membrane (73). 
E. coli is a gram negative bacterium, which means that this bacterium does not retain the 
crystal violet gram stain when washed with absolute ethanol and acetone and can be decolorized 
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to accept the counter stain (safranine or fuschine) which stain in red or pink. The peptidoglycan 
layer is responsible for inability of these bacteria to hold the crystal violet staining in gram 
staining test. Gram positive bacteria retain the crystal violet gram stain and remain the violet 
colored even after washing with absolute alcohol and acetone.  
Gram negative bacteria have a thin single layered peptidoglycan and gram positive bacteria 
have multilayered thick peptidoglycan layers. Teichoic acid is present in the cell wall of gram 
positive cells and absent in gram negative cells. An outer membrane and periplasmic space are 
only present in gram negative bacteria. Cell wall composition is different in the two kinds of 
bacteria as well. The gram negative bacterial cell wall is 70 Å-120 Å thick, two layered, and the 
lipid content is 20%-30% (high) whereas the murein content is low as 10%-20%. In gram 
positive bacteria, the cell wall is 100Å-120Å thick and two layered and the lipid content in the 
cell wall is low, whereas the murein content is high as 70%-80%. The lipopolysaccharides 
content is high in gram negative bacteria and low in gram positive bacteria.  
Intracellular structure  
When compared with eukaryotes, prokaryotes such as E. coli have very simple intracellular 
structures.  
Bacterial chromosome and the plasmid 
Escherichia coli do not possess a membrane enclosed nucleus like eukaryotes, but have a 
chromosome residing in the cytoplasm. Escherichia coli’s genetic material is a single circular 
chromosome located in the cytoplasm in an irregular shaped body called a nucleoid. The 
nucleoid contains the chromosomal DNA with its associated proteins (74). Therefore cellular 
information transfer processes such as DNA replication, transcription, and protein translation all 
occur in the same compartment. The bacterial chromosome is not packaged with histones to form 
chromatin like in eukaryotes but it takes very compact supercoiled structure. Other than the 
circular chromosome DNA other small independent pieces of DNA exist called as plasmids. 
Plasmids usually encode traits which are advantageous to E. coli but are not essential.  Plasmids 
can be easily transferred between bacterial species and therefore mediate horizontal gene 
transfer.  
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Ribosome  
E. coli has ribosomes in the cytoplasm that are used for protein synthesis (75,76), but the 
structure of the bacterial ribosome is different from that of eukaryotes. In Escherichia coli the 
most abundant intracellular structure is ribosome, which is the site for protein synthesis (45). 
Ribosomes link amino acid molecules in an order specified by the messenger RNA (mRNA) 
molecules. The ribosome binds an mRNA molecule and uses it as a template to determine the 
accurate sequence of the amino acids in a particular protein. Amino acids are brought to the 
ribosome by aminoacylated transfer RNA (tRNA) molecules (45). The ribosome consists of 
RNA and protein and therefore is a ribonucleoprotein. Each ribosome is divided into two parts, a 
smaller subunit that interacts with the mRNA and a larger subunit binding with the 
aminoacylated tRNA. Ribosomes from archea, bacteria and eukaryotes differ in their structures, 
sequences, sizes and ratios of protein to RNA. These differences aid in antibiotics to target the 
bacterial ribosomes without affecting the human ribosomes. E. coli ribosome is around 20 nm in 
diameter and composed of 65% ribosomal RNA and 35% ribosomal protein. E. coli has the 70S 
(S= Svedberg unit) ribosome and this 70S ribosome is composed of 30S small subunit and 50S 
large subunit. The 50S subunit consists of 23S RNA (2900 nucleotides), 5S RNA (120 
nucleotides) and 31 proteins. The 30S subunit contains the 16S RNA (consisting of 1540 
nucleotides) bound to 21 proteins (75). Proteins are complexed with the rRNA to form the 
ribosome(75).  
Cytoskeleton 
Earlier it was thought that prokaryotic bacteria do not possess a cytoskeleton. But with the 
advances in imaging techniques and structure determination it was concluded that filamentous 
structures does exists in the cytoplasm (77). The prokaryotic cytoskeleton is the collection of all 
structural filaments in prokaryotes. Previously bacteria were viewed as bags of cytoplasm, but 
the discovery of the prokaryotic cytoskeleton (78) and the localization of proteins to specific 
locations (79) within the cell lead to the idea of more complex cell structure.  These subcellular 
levels of organization have been called as “bacterial hyper structures” (80). 
Bacterial growth curve and its phases 
Bacterial growth is the division of one bacterial cell into two daughter bacterial cells by 
binary fission (81). Binary fission is a prokaryotic asexual reproduction method where a cell is 
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divided in two or more cells with each having a potential to grow into the size of an original cell. 
Under optimal conditions E. coli can grow and divide extremely rapidly, the bacterial population 
can double with every 20 min. This kind of division occurs without a spindle (82). During 
prokaryotic cell division, the single chromosomal DNA first replicates and the two products 
become attached to a different part of the cell membrane. When the cell begins to pull apart, the 
replicate and the original chromosome are separated and moved to the new two cells (82). With 
this kind of asexual reproduction the resulting daughter cells are genetically identical.  Both 
resulting cells from this kind of fission might not survive, but if the number of cells surviving 
exceeds unity on the average, the bacterial population undergoes exponential growth. Therefore 
bacterial growth in batch culture is modeled into four phases(83), which are: (A) lag phase, (B) 
exponential or log phase, (C) stationary phase, and (D) death phase. Finer subdivision of the 
phases are sometimes employed, which are: (A) lag phase, (B) early log phase, (C) log-
exponential phase, (D) early stationary phase, (E) stationary phase, (F) early death phase, (G) 
death phase.  
The lag phase is the bacterial growth phase during which the bacteria acclimatize 
themselves to the culture conditions. In this phase, synthesis of RNA, enzymes and other 
molecules occur but there is no accumulation of cells. In the exponential phase the characteristic 
feature is the cell number increments by cell doubling (84). The number of new bacteria 
appearing per unit time is proportional to the present population. If the growth is not limited, 
doubling will continue at a constant rate so the number of cells increases and the population 
doubles regularly over a defined time period. This is exponential growth and plotting the cell 
number against the time on a log scale produces a straight line. The slope of this line is the 
specific growth rate of the organism and it gives an idea of number of divisions per cell per time. 
The calculated rate from the slope of the curve depends on the growth conditions that affect the 
frequency of cell division and on the probability of daughter cell survival. The duration of the 
exponential phase depend on the size of the inoculum, capacity of the culturing medium and 
culture conditions to support the microbial growth. Biomass estimates needs to be plotted over 
time and the cell count and the dry weight are common methods of determining the biomass. 
But, exponential growth cannot continue indefinitely without replenishment of nutrients and 
removal of toxic waste products that accumulate in the medium. Stationary phase is the next 
phase that E. coli enters when grown in batch culture without perfusion to replenish nutrients and 
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remove waste. In the stationary phase, the bacterial growth and death rates are similar (85). The 
result is a horizontal portion of the growth curve called the stationary phase. The last phase is the 
death phase where bacteria die because they run out of nutrients and are killed by the 
accumulated toxic wastes.  
The specific growth rate is defined as the increase in the cell mass per unit time. The 
specific growth rate is given by the symbol, μ and the most common units are reciprocal hours 
(h
-1
). But it can be expressed in reciprocal minutes (min
-1
) or reciprocal seconds (sec
-1
) as well.  
The formula for calculating the specific growth rate is as follows (86): 
      
   
   
   
⁄  
     
 ; t2 > t1 
Where,  
mt1 and mt2 are biomasses at different time points (t1 and t2) respectively. 
μ = specific growth rate 
   = specific growth rate constant 
The difference between the growth rate and the specific growth rate is that, the growth rate 
of a microbial population is a measurement of increase of biomass over time and it is determined 
from the exponential phase. Growth rate is an important way of expressing ecological success of 
a strain or a species in adapting to its natural environment or the experimental environment 
imposed upon it.  
The inoculum effect 
The inoculum effect is a laboratory phenomenon that is described as a large increment in 
the minimum inhibitory concentration of the antibiotic when the number of inoculated organisms 
increases (87). Some bacteria that are susceptible to an antibiotic when the cultures are initiated 
with low density inoculum will be resistant to the same antibiotic when cultures are inoculated at 
higher densities (88). The importance of the inoculum effect was first described in the 1940s by 
several scientists. Fildes and colleagues found an inoculum effect associated with antibacterial 
activity of mercury (89). Lowell and colleagues determined that when Streptococcus  were 
transferred into growth medium containing sulfapyridine with high inoculum densities, these 
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originally susceptible strains were resistant and grew in that media very well (90).There are 
several implications of the inoculum effect (87). One implication is that understanding the 
inoculum effect may provide information about efficacy of an antimicrobial agent against 
infections involving large number of bacteria, such as in abscesses (87). Another importance of 
the inoculum effect is in the management of infections that involve high bacterial density and 
bacteria that express high concentrations of antibiotic degrading enzymes such as β-lactamase 
(87).    
Movement of the molecules in the cell 
The mobility of certain molecules inside the cells plays a very important role in well-
functioning of the cell. Nenninger et al. (91) showed in their study the importance of size of 
molecules in the cytoplasmic diffusion. The cytoplasm of both eukaryotes and prokaryotes are 
complex, crowded environments. The movement of molecules within the cytoplasm is 
constrained by a combination of viscosity, macromolecular crowding and specific interactions of 
the molecules with the other cell components (e.g. proteins, nucleic acids and the cytoplasmic 
membrane). Diffusion is regarded as the primary method of intracellular molecule movement 
and thus it plays an important role in controlling the rates of cell processes. In our study, the 
mobility of aptamers in the cytoplasm was an important factor in the hypothesis. Aptamers, 
being small molecules, were hypothesized to be mobile inside the cell.  
Terry et al. (92)  investigated the physical principles behind the mobility of molecules in 
cells. They discovered that the hydrodynamic radius (STOKES radius) is the deciding factor that 
drives the mobility of molecules through the plasmodesmata. Plasmodesmata are microscopic 
channels that transverse the cell walls of plant cells. Even though these plasmodesmata are 
involved in transport between cells they are composed of cytoplasm (93). Therefore the 
principles that govern the mobility of molecules through the plasmodesmata are valid for 
mobility of molecules in the cytoplasm as well. The STOKES radius or hydrodynamic radius is 
the radius of the hypothetical hard sphere that diffuses at the same rate as the molecule. This 
radius takes into consideration the shape and hydration effect of the molecule. Therefore a more 
extended molecule will have a larger STOKES radius than a compact molecule of the same 
molecular weight. As the STOKES radius of a molecule increases, its mobility decreases. Other 
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than the hydrodynamic radius, the diffusion coefficient also has an effect on the mobility of 
molecules inside the cells.  
 
Where RH = STOKES radius, kB = Boltzmann constant (in JK
-1
), D = diffusion coefficient 
(in m
2
s
-1), T=temperature in Kelvin, η= viscosity 
In liquids where there are interactions between solute and solvent molecules, the STOKES 
radius of a perfect sphere is proportional to the frictional coefficient and inversely proportional to 
the viscosity η. 
Techniques use for determining the mobility of molecules inside cells 
To determine the mobility of molecules in the cell cytoplasm, a variety of techniques have 
been used. One such technique is FRAP, Fluorescence Recovery After Photo bleaching (94,95). 
In FRAP, fluorescent molecules are photo bleached in a small area of the cell by a laser beam 
and the consequent diffusion of other surrounding non bleached fluorescent molecules into the 
bleached area leads to the recovery of the fluorescence that is recorded at a low laser power. The 
FRAP technique was first used in the 1970s when lipophilic or hydrophilic fluorescent 
molecules, like fluorescein, coupled with proteins and lipids were commonly utilized. Two very 
important factors can be inferred from the results of FRAP experiments. One is the mobile 
fraction of the fluorescent molecules and the mobility of these molecules. FRAP is the most well 
established method to characterizing the diffusion of fluorescently labeled molecules in liquid 
crystalline membranes. But under non ideal experimental conditions such as when the signal to 
noise ratio is low, when there are temporal fluctuations in the illumination or when there is 
bleaching during the recovery process (96). A more recent development is Pulsed-FRAP, which 
can be used for protein mobility measurements in the much smaller prokaryotic cells such as E. 
coli (97). 
The cloning of green flourescent protein (GFP), from jellyfish Aequorea victoria 
introduced a new era of flourescence tracking. This discovery made it possible to monitor the 
mobility of proteins in living cells without interference from microinjections.  Because of GFP’s 
relatively high photo stability, GFP-tagged molecules can be observed over long periods and the 
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resolution of light microscopy allows them to be located within the cells. The fusion of GFP to 
other proteins usually does not affect the function or localization of the proteins and therefore 
GFP is a very important for detecting mobility of molecules in the cell.  Other than these 
techniques Fluorescence Correlation Spectroscopy (FCS) (95,98) has also been used in 
experimentation in mobility of molecules in the cells. Fluorescence Correlation spectroscopy 
gives high resolution spatial and temporal analysis of extremely low concentrated biomolecules. 
In contrast to other fluorescence techniques in FCS primary parameter of interest is the not 
fluorescence emission, but the spontaneous intensity fluctuations caused by the minimal 
deviations of the small system caused by the thermal equilibrium. Therefore by the FCS 
technique fluctuations in the fluorescence signal is accessible which are caused by any physical 
parameter. Actually FCS measures the fluctuations in fluorescence intensity that results from 
diffusion of fluorescent molecules in and out of a small open volume and then uses 
autocorrelation analysis to detect the correlation of intensity deviation at one point in time to 
intensity deviation at later point in time. The diffusion coefficient is described by the rate of 
decay of correlation. Slower the molecule diffuses, longer the correlation continues. FCS 
technique does not interfere with the steady state of the molecule and also it is a noninvasive 
technique. But FCS can only function if concentration and volumes are reduced such that only 
few molecules are detected at the same time. These same techniques have been used to determine 
the mobility of RNA in the cytoplasm as well. 
Mobility of RNA 
Mobility of RNA in the cell 
The tracking of fluorescently labeled, microinjected and engineered or endogenous RNA 
demonstrated that ribosomal RNA and poly A RNA move freely and in a non-directional manner 
with a diffusion coefficient of 0.03-0.1 μm2s-1 within the nucleus (99,100).  Ritland and Shav-tel 
concluded that RNA motion inside the cell is rapid and non-directional.  Ido Golding and 
Edward. C. Cox has reported very significant discoveries regarding the mobility of RNA in the 
E. coli cells (101). In their study they have described a method for tracking down RNA 
molecules in E. coli cells which is sensitive to single copies of mRNA molecules. By their 
developed tracking method they have observed mobility of RNA molecules in the cytoplasm that 
is consistent with the known life history of RNA in prokaryotes. The main types of RNA motion 
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they have observed inside the cell were localized motion consistent with the Brownian motion of 
an RNA polymer bound to its template DNA and free diffusion. Other than this they also 
describe polymer chain dynamics that seem to be arising from chain fluctuation and chain 
elongation due to RNA transcription. Ido Golding and Edward.C.Cox used an mRNA detection 
system consisting of fluorescence protein GFP fused to the RNA bacteriophage coat protein MS2 
and a reporter RNA containing tandem repeats of MS2 binding sites. In addition they also 
monitored the RNA motion in the entire cell and they observed that the RNA molecule tend to 
spend more time near the cell pole than the center of the cell, which is due the increased drag 
experienced by the particles near the cell pole than the center of the cell also called as 
“hydrodynamic coupling” between the RNA molecule and the cell wall. Also this detection of 
RNA motion spanning the entire cell enabled them to give a quantitative value to the diffusion 
coefficient of the RNA-protein hybrids in the cell and the value is 0.03 µm
2
/sec. Another 
important discovery of their study is that they found movement of RNA molecules inside the cell 
is passive, which is proven by the fact that movement of RNA molecules in the cell is not 
inhibited by the metabolic poisons.  
A remarkable demonstration of this non-directional, rapid movement of RNA came from a 
set of experiments in which newly synthesized RNA was visualized at the site of the synthesis 
and then its export to cytoplasm was followed in living cells (99,100). These studies showed that 
RNA synthesized from genes positioned close to the nuclear envelope diffused away from their 
synthesis sites in all directions rather than to follow a straight path to nearest nuclear pore. This 
observation very strongly suggests the non-directional, diffusion based movement of RNA 
molecules in the nucleus. However this diffusion-based movement of RNA is associated with 
accessory proteins.  
RNA is a very mobile molecule in the cell.  The transport of RNA molecules from the 
nucleus to the cytoplasm is a fundamental cellular process. Compartmentalization in the 
eukaryotic cell as nucleus and cytoplasm and also the transition from prokaryotic co-
transcriptional translation of protein to eukaryotic physical separation of transcription of RNA 
and translation of proteins required evolution of a nuclear transport system. RNAs are 
transported from the nucleus to the cytoplasm after their synthesis in the nucleus and also newly 
synthesized proteins are imported and rapidly dispersed in the nucleus. How proteins and RNA 
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move within the cell and between the cytoplasm and the nucleus, how they find their targets was 
unknown for a long time. But with the invention of above mentioned techniques such as FRAP, 
GFP tagging and using time lapse spectroscopy these questions were answered.  
Selective Localization of RNA 
 Other than its movement from the nucleus to the cytoplasm, localization of RNA is 
another mode of RNA mobility. It is a long known fact that mRNA for certain proteins is 
localized in certain localizations of the cytoplasm (102). Known examples of localized RNAs 
can be divided into two categories. One category is the cellular mRNA transcribed in somatic 
cells, the localization of which results in synthesis of the encoded proteins at their sites of action 
(103) and the other category is the maternal mRNAs that are asymmetrically positioned in 
oocytes and aid in forming the axes of the embryo by establishing the concentration gradient of 
protein “morphogens” (104). Evidence for these localized mRNAs came from the results of in 
situ hybridization studies. Much attention has since been given to the mechanisms by which the 
mRNA location occurs. RNAs that are localized in the cell contain specific sequence elements 
termed “zip codes” (102,105). These zip codes are a class of cis-acting elements that occur 
within the 3’UTR of the mRNA and they aid in determining the stability, mobility and 
translational efficiency of the mRNA. Also mRNA zip codes determine the protein synthesis 
sites in the cell.  To identify the proteins that bind the zip code regions, Ross et al. (105)  
performed band shift assays, UV crosslinking and affinity purification. They identified a protein 
of 68 kDa that binds the proximal half (coding region) of the zip code in β-actin mRNA with 
high specificity. The zip codes regions are involved in peripheral distribution of the mRNA by 
interacting with proteins that mediate localization.  
β-actin mRNA is transported to peripheral locations in the cell by mechanisms that are not 
yet well known, although some information is known. One important observation is that actin 
mRNA movement is energy dependent. This was shown by Lantham et al. (106) who 
demonstrated that an ATP synthesis inhibitor, cordycepin, prevents RNA localization. Also 
localization does not require ongoing protein synthesis as it occurs at the presence of puromycin 
or cycloheximide (107). Most importantly the localization is inhibited by disruptors of actin 
cytoskeleton and not by disruptors of microtubule system, which indicates that localization or 
anchoring requires the actin cytoskeleton (107).  
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Mobility of Proteins 
It has been long known that RNA and protein move within the cell, especially within the 
cell nucleus of eukaryotes. Messenger RNA synthesized in the nucleus is quickly transported out 
of the nucleus to the cytoplasm and the newly synthesized proteins are on the other hand 
promptly transported in to the nucleus and dispersed. Phair et al. tested the mobility of proteins 
in the mammalian nucleus. They have measured the mobility of three important proteins in the 
nucleus. Those are nucleosomal binding protein (HMG-17), the pre-mRNA spicing factor 
SF2/ASF and rRNA processing protein fibrillarin in the nucleus of the living cells using the 
FRAP method and GFP fusion proteins. They show that these proteins move rapidly and 
completely into the nucleus after their synthesis. The protein movement is independent of energy 
indicating that proteins use a passive mechanism for the movement. Elowitz et al. had 
experimented on protein mobility in the cytoplasm of E. coli  using the similar technique as Phair 
et al. (108). They have made measurements in two different ways, one by photo bleaching the 
GFP fluorescence and photo activation of red emitting fluorescence state of GFP. They have 
calculated the diffusion coefficient values for GFP alone and GFP fusion protein in the E. coli 
cytoplasm. 
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CHAPTER 3: DRAGINS: DRUG BINDING APTAMERS FOR GROWING 
INTRCELLULAR NUMBERS 
Abstract 
One of the challenging requirements in cancer disease treatment today is maintaining high 
enough drug concentrations in order to obtain effective killing of cancer cells. Many attempts 
have been made to increase the intracellular concentrations of drugs that are based on “push” 
mechanism. In our novel approach we use a “pull” mechanism, meaning that we express a 
molecule inside the cell that has been selected specifically to bind with the drug molecule. The 
molecule expressed inside the cell is an aptamer. Aptamers are short, single stranded nucleic acid 
molecules ranging from about 15-100 nucleotides long. These small aptamer molecules are 
mobile inside the cells. Mathematical modeling of the effect of aptamer expression for increasing 
intra cellular drug concentration showed that this was possible. The initial model was developed 
for mammalian cells and the initial experimental testing of the hypothesis was done with 
Escherichia coli bacterial cells. Therefore now a new mathematical model for prokaryotic cells 
has been developed in parallel with the work described here. To test the hypothesis, E. coli BL21 
strain cells were transformed with plasmids from which aptamers were expressed. The effect of 
expressing several aminoglycoside aptamers on the toxicity of a range of aminoglycosides was 
observed over a 12 h period. Then neomycin-B aptamer and the neomycin-B were selected for 
future studies. The half maximal inhibitory concentration (IC50), which is the concentration of 
the drug required for 50% growth inhibition, were calculated to be decreased by 2 fold with 
aptamer expression. The Minimum Inhibitory Concentration (MIC) was also ~2 fold lower for 
cells with aptamer expression as compared to cells with control RNA expression. To determine 
the effect of aptamer expression on the intracellular drug concentration we used Cy3-
paromomycin. Cells with aptamer expression and cells with control RNA expression were 
incubated with Cy3-paromomycin and imaged directly or cell lysates were isolated and analyzed 
for fluorescence content by fluorimetry. Both the images and fluorimetry showed that cells with 
aptamer expression concentrate more Cy3- paromomycin compared to cells with control RNA 
expression.  In summary, this study gives insight towards a novel approach to increase the 
intracellular drug concentration by the use of small, mobile RNA aptamers. 
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Introduction 
A major challenge in cancer treatment today is providing a high enough drug concentration 
in order to obtain an effective killing of cancer cells. Cancer, medically known as malignant 
neoplasm is a disease which involves unregulated cell growth. Cancer cells have biological 
mechanisms which allow them to survive and perform unregulated cell growth. One of them is 
that cancer cells up regulate the expression of multi drug efflux pumps. Cancer cells that survive 
a drug treatment have elevated levels of drug pump called the Pgp (P-glycoprotein) or MDR 
(multi Drug Resistant pumps) (109), (110). These drug pumps allow the cells to survive, divide 
and grow under drug treatments which in turn result in more drug resistant cancer cell 
population.  Therefore, when undergoing chemotherapy cancer patients should be given very 
high concentrations of drugs in order to get an effective destruction of cancer cells. Most of the 
cancer drugs (chemotherapy) are cytotoxic reagents, that is providing these drugs in high 
concentration without targeted delivery, can be harmful to healthy cells as well. Incidentally this 
is one of the major causes of death in cancer patients.  Therefore increasing the effective intra 
cellular drug concentration is extremely important. 
Many efforts have been taken to combat the drug resistance (52). Some of these 
approaches are to target the pumps by drug or antibodies or to decline pump mRNA level of 
antisense DNA or RNAi and decrease the pump mRNA by targeting the appropriate mRNA 
genes and transcriptional factors. Some of these approaches could be successful one day to 
combat the drug resistance but so far none of them have been effective in war against drug 
resistance.  
By mathematical modeling it was predicted that by having a receptor for the drug inside 
the cells, intracellular drug concentration can be increased in mammalian cells (111). In that 
study small RNA aptamer that has high affinity and specific binding to the drug was used as the 
receptor. Aptamers have been used as intracellular agents to inhibit their targets or to control 
gene expression (28). But before moving to complex mammalian cells, in this study we tested 
the effect of intracellular expressed aptamer on bacterial growth at absence and presence of 
antibiotics and intracellular concentration of labeled antibiotics. Our hypothesis was that 
aptamers that are selected to bind with aminoglycoside antibiotics are expressed inside the 
bacterial cells they increase the susceptibility of the bacteria to the aminoglycoside. Here we 
38 
 
used in vitro selected RNA aptamers. The aminoglycoside RNA were cloned in to the bacterial 
system and the growth of those bacteria was monitored for 12 hour period at the condition of 
presence of the aminoglycoside and at the absence of the aminoglycoside. Then the IC50 values 
for aminoglycoside at each condition were calculated. The results show that aminoglycoside 
binding aptamers lower the IC50 value by 2-5 folds for the aptamer aminoglycoside binding 
ligands. Then we moved to determine the intra cellular drug concentration by using 
aminoglycosides modified with fluorescence ligand. The aptamer expressing cells and control 
RNA expressing cells were incubated with the fluorescent labeled aminoglycosides and then they 
were directed to fluorescent imaging and fluorescent spectroscopy. These results indicate that the 
aptamer expressing cells accumulate the fluorescent ligand labeled aminoglycosides more than 
the non aptamer expressing cells. Other than that now we are testing the predictions from the 
mathematical modeling.  
Materials and methods 
Chemicals  
Neomycin-B, Paromomycin, Kanamycin-A, Kanamycin-B, Tobramycin were obtained in 
their sulfate salt forms from the Sigma-Aldrich (Saint Louise, MO). CY3 (Lumiprobe, non 
sulfonated in 100% DMSO) labeled paromomycin was synthesized in our laboratory. Amberlite 
Weakly acidic cation exchange resin (Sigma-Aldrich), 9-fluorenyl-methyl chloroformate 
(FMOC-Cl) (Sigma-Aldrich), Borate buffer (0.37 M H3BO3, 0.37 M Na2B4O7, pH adjusted to 
8.5), H2O (HPLC grade; Sigma-Aldrich), Acetonitrile (HPLC grade; Sigma–Aldrich), HPLC 
column: YMC-Pack ODS AM12S05-2536WT AM303 250* 4.6 mm S-5 µM, 12 nm.  
Plasmids and Bacterial cells 
E. coli (DE3) star chemically competent cells were purchased from Invitrogen (Eugene, 
OR).  
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Figure 7. Plasmid map of the control RNA 
insert. pMU159 (ppTrc.pT7.MCS12/MU159) 
Ct11a plasmid used as the control RNA and it 
is the multiple cloning sequences downstream 
of T7 RNA polymerase promoter. This 
sequence has same length as aptamer RNA, but 
does not bind with aminoglycosides as the 
aptamers. 
Figure 8 
Figure 7 
Figure 8. Plasmid map of the Neomycin-B 
aptamer insert. Neomycin single unit aptamer; 
1merppTrc.pT7.a23NEO1Ax1/MU174. 
N1.3.Neomycin-B aptamer is cloned 
downstream of T7 RNA polymerase promoter. 
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Figure 10 
Figure 9 
Figure 9. Plasmid map of the tobramycin 
aptamer insert. Tobramycin aptamer; 
1merppTrc.pT7.a27TOB3Ax1/MU174-T1.3. 
Tobramycin aptamer is cloned downstream of 
T7 RNA polymerase promoter. 
 
Figure 10. Plasmid map of the Kanamycin 
aptamer insert. Kanamycin aptamer; 
1merppTrc.pT7.a25KNA1Bx1/MU174-K1.3. 
Kanamycin aptamer is cloned downstream of T7 
RNA polymerase promoter. 
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Table 1. Aptamer RNA sequences 
Aptamer Name Aptamer RNA Sequence 
Neomycin single unit aptamer 
(ppTrc.pT7.a23NEO1Ax1/MU174-N1.3) 
5’-GGACUGGGCGAGAAGUUUAGUCC-3’ 
Tobramycin single unit aptamer 
(ppTrc.pT7.a27TOB3Ax1/MU174-T1.3) 
5’-GGCACGAGGUUUAGCUACACUCGUGCC-3’ 
Kanamycin single unit aptamer 
(ppTrc.pT7.a25KNA1Bx1/MU174-K1.3) 
5’-CGCGAGUGGGCAUAGAAUUAUCGCG-3’ 
 
Equipment 
Bacterial growth curves were determined in Synergy2 plate reader (Biotek). Non-tissue 
culture treated, flat bottom 96-well polystyrene microtest plates were obtained from Falcon. 
Ninety six well plate sealing regular strength BREATHE-EASY (breathe easier sealing 
membrane for multi well plates) sealing membranes were purchased from Research Products 
International Corp. Micropipettes were purchased from Eppendorf and the Pipetmen were from 
Gilson. The test tubes were 14 ml Polystyrene round bottom tubes from Falcon. The incubator 
for cell culture was a Max-Q 4000 (Branstead Lab Inc.) 
Bacterial growth analysis 
E. coli BL21 cells were transformed with above mentioned plasmids and grown for about 
16 h at 37⁰C in Luria Bertani (LB) with 100 μg/mL ampicillin. Then the cultures were diluted 
about 100 times and incubated with 1 mM IPTG for 1 h at 37⁰C and 250rpm shaking. After the 1 
hour induction period incubation with aminoglycosides (neomycin-B, kanamycin-A, kanamycin-
B, tobramycin or paromomycin) was started and the bacterial growth was monitored by the plate 
reader (Biotek, model: Synergy HT) at 37⁰C and 250 rpm. The OD600 values were recorded at 
designated time points (every 1 h or 5 min time points over 12 h or 16 h time span) and the 
resulting growth curves were analyzed by Microsoft Excel software. By this method the half 
maximal inhibitory concentration (IC50) of the drugs at the presence and the absence of the 
aptamer expression was calculated.  The Minimum Inhibitory Concentration (MIC) of the 
Neomycin-B was determined by the serial dilution method. E. coli BL21 cells transformed with 
neomycin-B aptamer and the plasmid containing the control RNA were grown for about 16 h at 
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37⁰C in Luria Bertani (LB) broth with 100 μg/mL ampicillin. Then the cultures were diluted 
about 10 times and induced with 1 mM IPTG for 1 h at 37⁰C and 250 rpm shaking. After the 1 
hour induction period both cultures were plated on agar containing a dilution series of 
Neomycin-B. 
Intracellular drug concentration analysis with Cy3-paromomycin 
Cy3-paromomycin was used instead of the neomycin-B to determine the intra-cellular drug 
concentration. E. coli BL21 cells transformed with neomycin-B aptamer containing plasmid and 
the control RNA containing plasmid was primarily grown for about 16 h at 37⁰C and 250 rpm 
shaking in LB media with 100 μg/mL ampicillin. Then 1 mM IPTG was added to both cell 
cultures and they were incubated for 1 h at 37⁰C and 250 rpm shaking. Following the IPTG 
induction both cell cultures were concentrated by centrifugation at 9300 rcf for 1 min. The cell 
pellets were dissolved in 0.1 M LiCl, 50 mM K2HPO4 , pH 7 then centrifuged at 9300 rcf for 1 
min and suspended in 60 μl of 0.1 M LiCl , 50 mM K2HPO4 , pH 7. The samples were analyzed 
by fluorescence spectroscopy using a Varian fluorescence spectrophotomer set at emission 
maximum of 563 nm and excitation maximum of 510 nm. The emission slit was 5 nm and 
excitation slit was 10 nm and the PMT voltage was set at high.  
Extracellular drug concentration analysis by high performance liquid chromatography 
(HPLC) 
To determine the extra cellular drug concentration in the culture medium, neomycin-B was 
coupled with 9-fluorenyl-methyl chloroformate (FMOC-Cl). FMOC-Cl has a maximum 
fluorescence excitation at 260 nm wavelength and maximum fluorescence emission at 315 nm. 
       
9-fluorenyl-methyl chloro formate       Primary/secondary amine 
 
(FMOC-
Cl) 
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 The coupling reaction with Neomycin-B was performed in 1 mL in the presence of 1 mM 
FMOC-Cl, 0.185 M borate, pH 8.5. After addition of the sample containing neomycin-B, the 
mixture was vortexed for 50 sec and the incubated for 15 min in dark at room temperature. The 
coupling reaction was quenched by adding glycine to a final concentration of 4.76 mM. An 
YMC-Pack ODS C18 reverse phase column with 4.6 mm diameter was used to separate the 
reactants and reaction products. The separation was isocratic with a mobile phase of 10:90 = 
water: acetonitrile ratio and a flow rate of 1 mL/min. In all the experiments 10 μl of sample was 
injected into the column and column run was performed over a 20 min period at room 
temperature.  
To determine the concentration range of neomycin necessary for its detection, 0.25 and 2.5 
μM neomycin-B in water were separated by the HPLC procedure just described. In addition 
aqueous 2.5 µM kanamycin-A was reacted with 1 mM FMOC-Cl in a final volume of 1 mL and 
resolved by HPLC as described for neomycin-B. 
 To establish the background fluorescence in the assay, the analysis was performed on 
fluorescent reagent, FMOC-Cl with glycine and without glycine, which is the coupling reaction 
quenching reagent. Other control experiments to detect the background fluorescence that were 
performed to test for fluorescent compounds produced when FMOC-Cl was incubated with and 
without the 0.185 M borate buffer of pH 8.5. To establish the effect of the cell culture medium 
on the detection of neomycin B by this method, the same HPLC analysis was performed on 40% 
Luria Broth (LB) and 5 µM Neomycin-B in 40% LB.  
Extraction of neomycin-B from the LB culture media by cation exchange chromatography 
The cation exchange column was 2 cm in height and 1.5 cm in diameter and filled with an 
Amberlite resin. The Amberlite (CG50, Type1, Hydrogen form, Sigma-Aldrich) is a weakly 
acidic cation exchange resin (Sigma-Aldrich). After packing the column the resin was washed 
with 50 mL double distilled sterile water and then 5 mL of 5 µM Neomycin-B was passed 
through the column over a period of about 1 h to test the extraction conditions. The neomycin-B 
was eluted with three 1 mL aliquots of 1 M NH4OH. After the addition of each 1 mL of 1 M 
NH4OH, the column was incubated for 30 min to allow equilibrate. Five hundred microliter 
aliquots of the column elutions were used for the coupling reaction with the FMOC-Cl and 
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HPLC analysis. A sample of 0.5 mL of 4.1 µM Neomycin-B in 1 M NH4OH was reacted with 
0.5 mL of FMOC-Cl and used as a positive control for the HPLC separation. 
To determine if the cation exchange column could be used to extract neomycin-B from LB 
and neomycin-B mixture and for its successful analysis by fluorescence detection through 
HPLC, 5 mL of 5 μM neomycin-B in 100% LB was passed through the same cation exchange 
column, eluted, reacted with 1 mM FMOC-Cl and analyzed by HPLC analysis. As a positive 
control, 100% LB was also reacted with FMOC and resolved by HPLC.  
 
Results and discussion 
Effect of DRAGINS on aminoglycoside inhibition of cell proliferation 
A Decrease in the IC50 value was observed for neomycin-B with neomycin-B aptamer 
expressing cells as compared with the control. 
If aptamers increase the intracellular drug concentration then cell growth inhibition should 
be observed with a lower extracellular concentration of the drug in the presence of the 
intracellular aptamer as compared to cells expressing control RNA. To test the hypothesis that 
aptamers increase the intracellular drug concentration of a drug, BL21 E. coli cells were used as 
a model and aminoglycosides as the model drug. Aminoglycosides inhibit the growth of E. coli. 
We observed the growth of E. coli BL21 when incubated with antibiotic drugs and the effect 
aptamer expression on this growth by two methods of analysis: determination of the minimum 
inhibitory concentration (MIC) and determination of the 50% inhibitory concentration (IC 50) 
for each aminoglycoside. E. coli that expressed a control RNA of similar length to the aptamer 
RNA but did not bind aminoglycosides were used as the control. To determine the IC50, a range 
of aminoglycosides were tested against E. coli that expressed the cognate aptamer. To verify that 
aptamer expression was not toxic to cells we included a control condition of cells with and 
without aptamer expression that were cultured in the absence of antibiotics (Fig.11).  
By this test we evaluated the effect of the aptamer alone on bacterial growth. The results of 
these experiments (Fig. 11) showed that aptamer expression does not have an effect on bacterial 
growth. 
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To test the effect of aptamer expression on aminoglycoside toxicity, a range of 
aminoglycosides of different concentrations were incubated with cells that expressed aptamers 
and cells that expressed control RNA to observe the growth pattern of the cells (Fig. 12).  
Initially several RNA aptamers selected to bind with the specific aminoglycoside were 
expressed in E. coli and then incubated with the specific aminoglycoside and approximate IC50 
values were estimated (Table. 2).  
Once the neomycin aptamer and neomycin-B were selected as the aptamer-aminoglycoside 
pair, more concentrations of neomycin-B were analyzed with cell cultures with aptamer 
expression or with control RNA expression (Fig.14). 
 
 
 
Figure 11. Comparison of bacterial growth in cells with aptamer expression and cells with 
control RNA expression without the inclusion of antibiotic. 
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Figure 12. Comparison of bacterial growth with aptamer and control RNA expression. 
Cells that expressed the neomycin-B aptamer (red closed squares) (A) 7.5 μM kanamycin-A, (B) 
5 μM kanamycin-B, (C) 7.5 μM paromomycin, (D) 5 μM neomycin-B and (E) 5 μM tobramycin. 
In all cases, control cells with control RNA expression is shown in blue closed circles.
Figure 12 
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Table 2. Approximate IC50 values for neomycin-B with the neomycin aptamer 
 
IC50 value (μM) 
Lag phase Log phase Stationary phase 
Cells with 
aptamer 
Cells with 
control 
RNA 
Cells with 
aptamer 
Cells with 
control 
RNA 
Cells with 
aptamer 
Cells with 
control 
RNA 
Kanamycin-A 1 18.7 7.0 91.0 5.9 40.0 
Kanamycin-B 1 1 4.0 28.7 3.8 24.0 
Paromomycin 5.0 1 4.1 12.4 4.6 5.0 
Neomycin-B 4.7 1 5.8 74.7 4.5 12.4 
Tobramycin 4.4 1 3.4 22.3 4.1 8.9 
 
The results from the initial experiments showed that incubation with aminoglycosides 
resulted in decrease in the growth rate, extension of the lag phase and a decrease of cell density 
in the stationary phase for cells that expressed aptamers compared with cells that expressed the 
control RNA. This allowed crude estimates of IC50 for each phase of the cell cycle (Table 1). 
The aptamer-aminoglycoside pair that showed the best difference in IC50 values and MIC values 
among the cells expressing the aptamers and cells expressing the control RNA was selected for 
further experimentation. Therefore, the neomycin aptamer with neomycin-B was selected as this 
aptamer-aminoglycoside pair because they showed the most consistent separation in IC50 values 
and MIC values between the cells expressing the aptamer and cells expressing the control RNA. 
Further experiments were performed to determine the IC50 for neomycin-B inhibition of cell 
proliferation of cells that expressed control RNA compared to cells that expressed the neomycin-
B RNA aptamer (Fig. 13). 
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Figure 13. Comparison of bacterial growth with and without IPTG induction for cells that 
express neomycin-B aptamers.  These results show that when the neomycin-B aptamer is 
expressed (induced by IPTG) decreases the growth of bacteria in the presence of 
aminoglycosides. aptamer (closed squares) (A) 7.5 μM Kanamycin-A, (B) 5 μM Kanamycin-B, 
(C) 7.5 μM Paromomycin, (D) 5 μM Neomycin-B, (E) 5 μM Tobramycin. In all cases cells 
without IPTG induction is shown in closed circles. 
 
Figure 13 
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Figure 14. Comparison of bacterial growth with neomycin aptamer expression. The final 
cell densities were normalized to the no-drug control sample for cells that expressed the 
neomycin aptamer (closed squares) and with cells that expressed the control RNA (closed 
circles). (A) 1 h time point (B) 6 h time point. 
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From these data, more accurate estimates were made of IC50 values than the estimates 
shown in Table 1.  These values are shown in Table.2. Neomycin-B molecules inside the cell at 
the presence of the aptamer can exists in two forms, one is as free neomycin-B and other is the 
neomycin-B bound to the aptamer. Of these two forms only free neomycin-B that is not bound 
with the aptamer can be utilized for cell killing by interacting with the ribosome. Therefore the 
results in figure 12, 13 and 14 demonstrate that the free drug concentration inside the cell 
increases when the neomycin-B aptamer is expressed which leads to cell killing.    
Table 3. IC50 values for neomycin aptamer with neomycin-b 
 
Aptamer expressing cells 
(μM) 
With control RNA expressing 
cells (μM) 
Lag phase 2.5 5 
Log phase 3.6 4.7 
Stationary phase 4.0 6.2 
6hour time point 2.3 5.9 
 
A Decrease in the minimum inhibitory concentration (MIC) was observed for          
neomycin-B with neomycin-B aptamer expressing cells as compared with the control. 
Another approach to test the hypothesis of that aptamers increase the intracellular drug 
concentration is to calculate the minimum inhibitory concentration or the MIC value. The MIC is 
the minimum concentration of a drug required to inhibit the growth after an overnight 
incubation. MIC values were calculated for cells that expressed aptamers and cells that expressed 
the control RNA, (Fig.15) & (Table 4).  
 
 
 
 
51 
 
Table 4. Minimum inhibitory concentration values for neomycin-B for cells with neomycin 
aptamer expression and cells with control RNA expression. 
Neomycin-B concentration 
(μg/mL) 
Cells with control RNA 
expression 
Cells with aptamer expression 
12.5 No growth No growth 
6.25 No growth No growth 
3.12 No growth No growth 
1.56 Growth No growth 
1.00 Growth No growth 
0.78 Growth Growth 
0.50 Growth Growth 
0.39 Growth Growth 
0.19 Growth Growth 
0.09 Growth Growth 
 
Table 5. Controls in the minimum inhibitory concentration experiments 
Plate LB+ Agar 
Neomycin-B 
1mg/mL 
Cells 
Growth 
Conditions 
1 + - - No growth 
2 + + - No growth 
3 + + + No growth 
4 + - + Growth 
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Figure 15. Comparison of visible bacterial growth on agar plates with aptamer expression 
and with control RNA expression A) Cells neomycin-B aptamer and cells expressing control 
RNA was spotted on agar plate with 1.56 μg/mL neomycin-B, (B) Cells expressing neomycin-B 
aptamer and cells expressing control RNA were spotted on agar plates with 1.00 μg/mL 
neomycin-B. (C) Cells expressing neomycin-B aptamer and cells expressing control RNA were 
spotted on agar plates with 0.78 μg/mL neomycin. 
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Effect of DRAGINS on intracellular drug concentrations 
The previously described results showed that DRAGINS affect the growth of bacterial 
cells because aptamer expressing cells have lower IC50 and MIC values than the control RNA 
expressing cells. This suggests that the intracellular concentration of neomycin-B was increased 
in cells that expressed aptamers. To test this conclusion, I used a direct test of the effect of 
DRAGINS on the intracellular drug concentration, which was to measure the cell uptake of 
paromomycin labeled with Cy3 that was analyzed by fluorescence imaging and fluorescence 
spectroscopy.  I also attempted to determine the extracellular drug concentrations with condition 
using High Performance Liquid Chromatography (HPLC) to analyze the aminoglycoside 
modified by chemical linkage to a fluorescent moiety. In these experiments described in this 
section I used cells that expressed neomycin-B aptamer and as the control I used cells that 
expressed control RNA, which is of the same length as the aptamer, but does not bind with the 
aminoglycoside drug as the aptamer.  
Effect of aptamer expression on the Intracellular Cy3-paromomycin concentration  
Increase in fluorescence signal was observed for cells with aptamer expression after 
incubating with Cy3-paromomycin as compared to controls. To verify the hypothesis that 
aptamers increase the intracellular drug concentration, Cy3- paromomycin was used instead of 
neomycin-B as neomycin-B does not have any chromophores or fluorophores for its ready 
detection. First an imaging approach was taken to determine the effect of aptamers on 
intracellular Cy3-paromomycin levels (Figs. 16 & 17). For this initial experiment 3μM of Cy3-
paromomycin was selected as this concentration was used in our growth analysis experiments. 
As evident by these results, aptamer expressing cells have more Cy3-paromomycin 
intracellular drug molecules than the cells expressing control RNA.  To verify the results, I 
performed the same experiment with more controls to account for background fluorescence 
coming from cells, the background fluorescence coming from Cy3-paromomycin without any 
cells, and the filter used in these experiments.  
It is clear from the above results that aptamer expressing cells have higher intracellular 
drug concentrations than the cells expressing the control RNA, because the fluorescence image 
of letter “L” written by cells expressing the aptamer incubated with Cy3-paromomycin is more 
intense than the rest of the fluorescence images of letter “L” written by the cells expressing the 
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control RNA incubated with Cy3-paromomycin, cells that were not incubated with Cy3-
paromomycin or the just the filters used in these experiment.  
But this approach is more of a qualitative analysis. For a more quantitative approach I used 
fluorescence spectroscopy with Cy3-paromomycin. I determined the internal fluorescence 
intensity for three different concentrations of Cy3-paromomycin (Fig. 18). In these experiments I 
introduced a new control which is named as “zero time incubation”. In this sample cells were 
grown in a similar fashion as the rest of cell cultures. Cy3-paromomycin was introduced just 
before precipitating the cells for their analysis. This sample was done to account for the any 
adhered Cy3-paromomycin to the cell surface. 
The results showed that cells expressing the neomycin-B aptamer have higher fluorescence 
emission at 563nm, the Cy3 fluorescence maximum, compared with cells expressing the control 
RNA and when the back ground fluorescence coming from cells and adhered fluorescent 
molecules were subtracted from the fluorescence spectrum of cells expressing the aptamer and 
cells expressing the control RNA this difference was much clearer.  
 
                                  
Figure 16 
A 
B 
C 
D 
55 
 
Figure 16. Comparison of intracellular Cy3-paromomycin in cells expressing the neomycin-
B aptamer and cells expressing the control RNA. (A) Fluorescence image of cells with 
aptamer expression taken at 400pmt voltage. (B) Fluorescence image of cells with aptamer 
expression taken at 300pmt voltage. (C) Fluorescence image of cells expressing the control RNA 
taken at 400pmt voltage. (D) Fluorescence image of cells expressing the control RNA taken at 
300pmt voltage. 
 
Figure 17 
A 
B 
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D 
E 
Figure 17.  Fluorescence images of cells with 
and without expressed neomycin-B aptamer 
and the controls for the images. (A) 
Fluorescence image of just the filter (B) 3μM 
Cy3 labeled paromomycin, (C) cells with 
neomycin-B aptamer without any antibiotic 
incubation, (D) cells expressing the neomycin-B 
aptamer incubated with 3μM Cy3-paromomycin, 
(E) cells expressing the control RNA incubated 
with Cy3-paromomycin. All images obtained 
with 400pmt voltage. 
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Figure 18. Fluorometry of cells with and without expressed neomycin-B aptamer and the 
controls. (A) 3μM Cy3-paromomycin incubated with cells with aptamer expression and cells 
with control RNA expression after the no antibiotic control was subtracted from both. (B) 5μM 
Cy3-paromomycin incubated with aptamer expressing cells and cells expressing the control 
RNA with controls of no antibiotic and zero time incubation. (C) 5μM Cy3-paromomycin 
incubated with aptamer expressing cells and cells expressing the control RNA after the no 
antibiotic control and zero time incubation control subtracted from both. (D) 7μM Cy3- 
paromomycin incubated with aptamer expressing cells and cells expressing the control RNA 
with controls of no antibiotic and zero time incubation. (E) 7μM Cy3-paromomycin incubated 
with aptamer expressing cells and cells expressing the control RNA after no antibiotic control 
subtracted from others. (F) 7μM Cy3-paromomycin incubated with aptamer expressing cells and 
Figure 18 
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cells expressing the control RNA after no antibiotic control and zero-time incubation control 
subtracted from both. 
To verify that the increase in intracellular Cy3- paromomycin in cells expressing the 
neomycin-B aptamer was due to the paromomycin moiety and not Cy3, I performed several 
other control experiments. Cy3 and paromomycin of the similar concentrations were mixed in 
the same culture tube and incubated with the cells. Other cell cultures were incubated with Cy3 
and or paromomycin (Fig. 19). 
As shown by these results, when neomycin-B aptamer expressing cells were incubated 
with Cy3- paromomycin the fluorescence at 563nm, which is the CY3 fluorescence emission 
maximum, was highest. This result indicates that cells expressing neomycin-B apatmer have the 
highest intracellular concentration of Cy3-Paromomycin. In another test that aptamer expression 
causes the increase in intracellular Cy3-paromomycin concentration, experiments to observe 
Cy3-paromomycin uptake by the cells were performed with and without IPTG to induce aptamer 
or control RNA expression (Fig.20).  
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Figure 19. Fluorometry of aptamer expressing cells and control RNA expressing cells 
incubated with CY3 labeled paromomycin, CY3, CY3 and paromomycin.  
IPTG induces the aptamer RNA and control RNA synthesis, therefore cell cultures 
incubated with IPTG will have higher levels of plasmid-expressed RNA than in the absence of 
IPTG. In this experiment, cells incubated with IPTG and expressing the neomycin-B aptamer 
showed the highest fluorescent emission peak around 563nm indicating that these cells have the 
highest intracellular Cy3-paromomycin (Fig.20). 
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Figure 20. Fluorescence spectra of aptamer expressing cells and cells expressing control 
RNA with and without IPTG induction. Aptamer expressing cells and cells expressing the 
control RNA was incubated with Cy3-paromomycin and directed to fluorescence spectroscopy. 
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Measuring the extracellular neomycin-B concentration 
To determine the concentration range of FMOC-neomycin-B that can be detected by this 
method 0.25μM and 2.5μM of neomycin-B were tested by modifying with FMOC-Cl and 
analyzed by HPLC. 
 
 
Figure 21. HPLC chromatograms obtained by C18 RP column and 90:10=Acetontrile: 
Water isocratic elution. (A) 2.5μM Neomycin-B (B) 0.25μM Neomycin-B. 
Figure 21 
A 
B 
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As evident from the chromatogram 2.5 μM neomycin-B (aq) around 14 minutes retention 
time and when the neomycin-B was diluted 10 times to a concentration of 0.25 μM, then the 
peak around 14 minutes retention time was observed but with much less intensity. Thus, this 
result shows that 2.5 μM neomycin-B can be detected by this method. To verify the peak that I 
observed at around 14 min is due to neomycin-B rather than a system artifact, 2.5 μM 
kanamycin-A (aq) was analyzed in the same way by HPLC. Kanamycin-A is an aminoglycoside 
with similar properties to neomycin-B. 
 
 
Figure 22. HPLC chromatograms obtained by C18 RP column and 90:10=Acetontrile: 
Water isocratic elution. (A) 2.5 μM Kanamycin-A (B) 2.5 μM Kanamycin-A (C) 2.5 μM 
Neomycin-B (D) 0.25μM Neomycin-B. 
Figure 22 
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In the kanamycin-A chromatogram peak around 5 min retention time could be observed in 
repeated experiments. But the peak observed at 14 min for Neomycin-B was absent. Therefore 
the kanamycin-A peak of 5 min and neomycin-B peak of 14 min are unique to the each 
aminoglycoside. This is evident that the 14 min retention time peak is due to neomycin-B.  
The next step was to observe whether this method can be used to detect neomycin-B in 
culture medium. All bacterial cell cultures for this project were grown in Luria Broth (LB), this 
culture media was incubated with FMOC-Cl and analyzed by HPLC. For the FMOC-Cl reaction, 
the sample was diluted to 40% LB. The chromatograms of 40% LB and 2.5 μM neomycin-B 
were compared (Fig. 23).  
 
  
Figure 23. HPLC chromatograms obtained by C18 RP column and 90:10=Acetontrile: 
Water isocratic elution. (A) 2.5μM Neomycin-B (B) 40% LB. 
Figure 23 
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The chromatogram of 40% LB did not have any peaks around the retention time of 14 min, 
which is the position of the neomycin-B peak.  Therefore it seems the LB does not interfere in 
the detection of neomycin-B. I then analyzed a 2.5μM Neomycin-B in 40% LB (Fig. 24). 
As been evident by the chromatogram the peak that I observed around 14 min retention 
time is for 2.5μM neomycin-B (aq) is not visible in 2.5μM neomycin-B in 40% LB. It appears 
from this chromatogram that the presence of LB interferes with the ability to detect neomycin-B.  
 
 
 
Figure 24. HPLC Chromatograms of (A) 40% LB (B) 2.5μM Neomycin-B in 40% LB (C) 
2.5μM Neomycin-B.  
Figure 24 
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To establish the background fluorescence coming from the other components of the 
coupling reaction the same reaction and HPLC analysis was performed on the fluorescent agent, 
FMOC-Cl incubated with and without glycine, which was the quenching reagent for the coupling 
reaction, or with and without the borate buffer (Fig. 25).  
The resulting chromatograms show that the other components in the reaction mixture do 
not create a peak that migrates in the same position as FMOC-Cl-neomycin-B.  
 
 
 
Figure 25. HPLC Chromatograms of (A) 1mM FMOC-Cl with 0.1M Glycine with 0.185M 
borate buffer (B) 1mM FMOC-Cl without glycine and borate buffer (C) 1Mm FMOC-Cl with 
0.185M borate buffer and without glycine (D) 2.5μM Neomycin-B. 
Figure 25 
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To verify that the fluorescent reagent that I used, FMOC-Cl, was not a limiting reagent for 
the coupling reaction I carried out experiments that reacted 2.5 μM Neomycin-B in 40% LB with 
2 mM, 10 mM and 1M FMOC-Cl and analyzed these samples by HPLC (Fig. 26). 
 
 
 
Figure 26. HPLC Chromatograms of 2.5μM Neomycin-B and 40% LB coupled with 
(A) 2mM FMOC-Cl (B) 10Mm FMOC-Cl (C) 1M FMOC-Cl and (D) 2.5μM Neomycin-B in 
40% LB (F) 2.5μM Neomycin-B.  
Figure 26 
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The results showed that increasing the FMOC-Cl concentration does not result in the 
neomycin-B peak becoming visible in the neomycin-B and LB mixture. Therefore, it is unlikely 
a limitation. 
Because the reason for the loss of the Neomycin-B peak from the neomycin-B and LB 
mixture seemed to be due to LB interference, the neomycin-B was extracted from the mixture of 
neomycin-B and LB by the use of cation exchange chromatography. 
  
 
 
Figure 27. HPLC Chromatograms of cation exchange column 1M NH4OH elutions of 5μM 
Neomycin-B (aq) (A) first 1M NH4OH elution (B) second 1M NH4OH elution (C) third 1M 
NH4OH elution (D) Positive control: 4.1μM Neomycin-B in 1M NH4OH. 
Figure 27 
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To determine the ability of cation exchange chromatography to extract neomycin-B from 
bacterial cultures with LB, 5μM of neomycin-B was passed down the cation exchange column, 
eluted by three separate 1M NH4OH elutions, reacted with FMOC-Cl, then analyzed by HPLC. 
The resulting chromatograms showed that the elution 1 and 2 with 1M NH4OH had the same 
peak around 7 min retention time which is visible in the positive control of 4.1 μM Neomycin-B 
in 1M NH4OH that had not been run through the cation exchange column. Therefore it was 
decided that neomycin-B can be extracted from the cation exchange column and the FMOC 
derivative can be detected by HPLC. The next step was to determine how LB alone would 
appear on the chromatogram after passing through the cation exchange column, reaction with 
FMOC-Cl and resolution by HPLC.  To serve that purpose 100% LB was applied to the column 
and then eluted consecutively three times with 1M NH4OH. 
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Figure 28. HPLC Chromatograms of cation exchange 1M NH4OH elutions of 100% LB (A) 
first 1M NH4OH elution (B) second 1M NH4OH elution (C) third 1M NH4OH elution (D) 
positive control: 50% LB in 1M NH4OH.  
Chromatograms of the first two elutions of 50% LB in 1M NH4OH, showed a peak at around 8 
min retention time (Fig. 24). This peak was close to the FMOC-neomycin-B peak and could 
interfere with the latter.  A mixture of 5 μM Neomycin-B and 50% LB was then through the 
cation exchange column and eluted three consecutive times with 1M NH4OH. The eluted 
samples were reacted with FMOC-Cl and analyzed by HPLC.  
 
 
 
Figure 29. HPLC Chromatograms of cation exchange with 1M NH4OH elutions of 5μM 
Neomycin-B in 100% LB (A) first 1M NH4OH elution (B) second 1M NH4OH elution (C) third 
1M NH4OH elution (D) Positive control: 4.1μM Neomycin-B in 50% LB with 1M NH4OH. 
Figure 29 
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The three 1M NH4OH elutions contained two peaks around 6.8 min and 7.7 min, whereas 
the positive control sample that was not run through the cation exchange column also contained 
the peaks around 6.8 min and 7.5min. These 6.8 min and 7.5 min peaks are the characteristic 
peaks observed for 100% LB passed through the cation exchange column and resolved by HPLC 
and also its positive control sample that was not run through the cation exchange column which 
is 50% LB in 1M NH4OH (Fig. 24). As demonstrated from these results the chromatogram of 
LB-FMOC and LB-neomycin-B-FMOC cannot be distinguished from each other. This result 
indicates extracting the Neomycin-B from the Neomycin-B and LB mixture was not successful. 
This could be because LB and aminoglycosides might have molecules with a very similar 
polarity and they both elute around the same retention time in the HPLC and also elute together 
from the cation exchange column as well. 
Conclusions and future directions 
The results presented here show the ability of in vivo expressed aminoglycoside aptamers 
to increase aminoglycoside concentrations inside the cells. First we observed the effect of 
expressing aptamers inside the cells. This shows that expressing aptamers inside the cells do not 
affect the growth of E. coli bacterial cells in the absence of their ligands. Then we analyzed the 
neomycin-B aptamer expressed by cells that were incubated with different concentrations of 
aminoglycosides. The results showed that aptamer expression decreased the growth bacteria in 
the presence of a range of aminoglycoside concentrations when compared with control E. coli 
that expressed control RNA that did not bind aminoglycosides. In addition we also tested the 
effect of aptamer expression by varying the presence or absence of IPTG, which induces the 
RNA aptamer expression. Cells incubated with IPTG in which the neomycin-B aptamer was 
expressed grew more slowly than cells in the absence of IPTG in which the aptamers were not 
induced when incubated with aminoglycosides. Using the neomycin-B aptamer and the 
neomycin-B we determined the IC50 and MIC values, which both decreased by about 2-fold for 
cells with the aptamer expression compared to cells with control RNA expression.  
If the increased effectiveness of neomycin-B cell killing was due to the proposed 
mechanism as defined by the mathematical model, then it is predicted that the intra cellular 
aminoglycoside concentration should increase with aptamer expression. We used Cy3-
paromomycin to measure relative intracellular concentrations of aminoglycoside with and 
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without aptamer expression. Cells that expressed control RNA or aptamer were incubated with 
Cy3-paromomycin and the spectra of these cell lysates were determined. These results also 
showed that the cells with aptamer expression contained more the Cy3-paromomycin compared 
with cells that expressed the control RNA. To confirm that the increased cellular content of Cy3-
paromomycin was due to aptamer recognition of the paromomycin and not to the Cy3 tag, we 
compared the effect of aptamer expression on the intracellular content of Cy3-paromomycin, 
Cy3 or a mixture of Cy3 and paromomycin. The results showed an increase in intracellular 
fluorescence only for aptamer-expressing cells that had been incubated with Cy3-paromomycin. 
Finally fluorometric analysis was done for aptamer expressing cells and control RNA expressing 
cells with and without IPTG induction. These results indicate that aptamer-expressing cells 
(IPTG induced) accumulate higher intracellular concentrations of Cy3-paromomycin compared 
with cells that are not induced by IPTG.  
Our next specific aim was to determine if the presence or absence of aptamers caused an 
effect on the extracellular drug concentration. For that purpose, HPLC detection of fluorescent 
ligand labeled aminoglycoside was used. First we investigated the neomycin-B concentration 
range that can be detected with this method. It was evident from the results that the concentration 
range of neomycin-B used in the experiments could be detected by HPLC. Kanamycin-A was 
used as a control to determine if the peaks observed for neomycin-B might be due to neomycin-B 
or an artifact of sample preparation. The results showed that neomycin-B and kanamycin-A 
chromatogram were separated by HPLC to give distinctive peaks. Both aminoglycosides had 
been modified with FMOC-Cl. Because the bacterial culture was done in LURIA broth (LB) 
media we tested whether neomycin-B could be detected in the presence of LB. The HPLC 
chromatograms for 40% LB showed distinct peaks for the contents of LB, but neomycin-B could 
not be detected against this background. This could be because the some component in LB was 
interfering with the neomycin-B separation in the chromatographic column. Then control 
experiments were performed to see whether the fluorescent reagent used, FMOC-Cl, was 
limiting. It was concluded that no interfering fluorescence was coming from the other contents in 
the reaction mixture other than LB. Therefore it was decided to extract the neomycin-B from the 
LB, neomycin-B mixture by the use of cation exchange chromatography. In order to determine 
the feasibility of the extracting neomycin-B from LB by the cation exchange chromatography 
first neomycin-B was passed through the cation exchange column and resolved by the 
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established HPLC method. This concludes that neomycin-B could be extracted from the cation 
exchange column with the established conditions and the elutions could be analyzed by the 
HPLC by the used method. Then LB alone was passed through the cation exchange column and 
then resolved by the HPLC method. The three consecutive 1M NH4OH elutions gave the same 
distinctive peaks on HPLC as the LB that was not passed through the cation exchange column 
proving that LB could be extracted from the cation exchange column and could be resolved by 
the established HPLC method. Then mixture of LB and neomycin-B was passed through the 
cation exchange column and the elutions of the column were directed to established HPLC 
method along with positive control of neomycin-B and LB mixture that was not passed through 
the cation exchange column. The chromatograms of the 100% LB and the neomycin-B, LB 
mixture show the same peaks. This result proves that cation exchange column cannot be used to 
extract neomycin-B from the LB, neomycin-B mixture. Therefore we can use another method 
such as aminoglycoside modified with fluorescence ligand as cy3-paromomycin with HPLC or 
fluorescence spectroscopic detection for extracellular drug concentration variation determination. 
In 2009 our group collaborated with Boushaba and Levine, mathematicians in the 
Department of Mathematics at Iowa State University, to evaluate if aptamers could concentrate 
drugs inside cells. Our data shows that aptamer expression works as predicted by the 
mathematical modeling.  
With these results it is evident that aptamer expressing cells are inhibited in their growth 
more by aminoglycoside antibiotics compared to cells expressing the control RNA. This effect is 
evidenced by lower IC50 and MIC values of the aptamer expressing cells than cells expressing 
control RNA. These results also confirmed that the aptamer expressing cells also have higher 
intracellular free drug number than cells expressing control RNA. From the results of 
experiments with Cy3-paromomycin, it could be concluded that cells expressing the neomycin-B 
aptamer have more Cy3-paromomycin in the intracellular environment than the cells expressing 
the control RNA. These results demonstrate that cells with aptamer expression accumulate 
higher total intracellular drug concentrations (both bound with aptamer and unbound) than cells 
expressing the control RNA.  
In our project we assume mobility of the aptamers plays an important role. Therefore it is 
important to observe the effect of the aptamer mobility. To test the effect of aptamer mobility for 
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increasing the intracellular drug concentration we can use single unit aptamers attached to longer 
RNA molecules that does not affect the aptamer’s characteristic properties and binding ability. 
Another experiment that can be performed in order to serve the same purpose is to use aptamers 
attached with SHINE-DALGARNO sequence (ribosome binding sequence) and then ribosome 
binding will increase the apparent molecular weight of the aptamer thereby decreasing the 
mobility of the aptamer molecule. Other than this, it is important to test the effect of the multi-
drug efflux pumps. According to the model, the aptamers work against the drug efflux pumps. 
AcrD is the drug efflux pump that is expressed by E. coli cells to export the aminoglycoside 
antibiotics. Therefore bacterial growth assays and intracellular drug concentration determination 
assays can be performed with cells expressing aptamers and cells expressing control RNA with 
cells engineered to over express AcrD pump and also with cells in which the AcrD is deleted. 
These experiments could give a more clear understanding of the mechanism by which aptamers 
increase intracellular drug numbers with regard to action of multi drug efflux pumps. 
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